Page last updated: 2024-09-05

lenalidomide and Myelodysplastic Syndromes

lenalidomide has been researched along with Myelodysplastic Syndromes in 405 studies

Research

Studies (405)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	94 (23.21)	29.6817
2010's	256 (63.21)	24.3611
2020's	55 (13.58)	2.80

Authors

Authors	Studies
Boultwood, J; Cattan, H; Christensson, B; Emanuelsson, EK; Forsblom, AM; Hellström-Lindberg, E; Jädersten, M; Merup, M; Nilsson, L; Pellagatti, A; Samuelsson, J; Sander, B; Wainscoat, JS	1
Abedi, M; Hoeg, R; Krishnan, R; Pham, B; Richman, C; Tuscano, J	1
Bourbon, E; Groarke, EM; Heiblig, M; Patel, BA; Sujobert, P	1
Ali, NA; Chan, O; Komrokji, R; Lancet, J; Padron, E; Sallman, D	1
Bernard, E; Cavelier, L; Dybedal, I; Ebeling, F; Ejerblad, E; Flogegård, M; Garelius, H; Göhring, G; Grønbaek, K; Hellström-Lindberg, E; Jädersten, M; Kittang, AO; Lorenz, F; Marcher, CW; Möllgård, L; Nilsson, L; Nørgaard, JM; Öster Fernström, A; Papaemmanuil, E; Rasmussen, B; Saft, L; Tobiasson, M	1
Goede, JS; Wilk, CM	1
Bazinet, A; Bravo, GM	1
Aul, C; Bock, O; Buesche, G; Ebert, BL; Ganser, A; Germing, U; Giagounidis, A; Göhring, G; Kreipe, H; Ribezzo, F; Schlegelberger, B; Schneider, RK; Teoman, H	1
Seymour, JF; Wei, AH	1
Buzoianu, AD; Ciechanover, A; Dima, D; Drula, R; Ghiaur, G; Gulei, D; Iluta, S; Iuga, C; Tomuleasa, C	1
Beach, CL; Fenaux, P; Franco-Villalobos, C; Giagounidis, A; Hu, A; Morison, J; Pelligra, CG; Platzbecker, U; Santini, V; Tang, D	1
Arai, A; Miura, I; Sakai, H	1
Abdelmagid, M; Al-Kali, A; Badar, T; Begna, K; Elliott, MA; Fleti, F; Foran, JM; Gangat, N; Ketterling, RP; Khera, N; Pardanani, A; Reichard, KK; Singh, A; Tefferi, A	1
Bonanni, F; Breccia, M; Buccisano, F; Cicconi, L; Criscuolo, M; Di Veroli, A; Fenu, S; Fianchi, L; Gumenyuk, S; Gurnari, C; Latagliata, R; Maciejewski, JP; Maiorana, G; Maurillo, L; Niscola, P; Piccioni, AL; Piciocchi, A; Piedimonte, M; Salutari, P; Santopietro, M; Sarlo, C; Scalzulli, E; Soddu, S; Tafuri, A; Voso, MT	1
Ichikawa, M	3
Invernizzi, R	1
Berdeja, J; Bhagat, P; Braunschweig, I; Donnellan, WB; Fehn, K; Goldfinger, M; Gonzalez-Lugo, JD; Gritsman, K; Jasra, S; Kambhampati, S; Kazemi, M; Kim, M; Kornblum, N; Mantzaris, I; Pradhan, K; Remy, C; Shah, N; Shastri, A; Sica, RA; Steidl, U; Verma, A; Will, B; Yacoub, A	1
Abe, S; Furukawa, H; Kameoka, J; Kobayashi, M; Kodera, T; Murakami, K; Nomura, J; Oka, Y; Okitsu, Y; Shirota, Y; Takahashi, S; Takeda, T	1
Graafsma, J; Hoogendoorn, M; Kibbelaar, R; Rozema, J; van Roon, E; Veeger, N	1
Garcia-Manero, G; Komrokji, RS; Volpe, VO	1
Gattermann, N; Germing, U; Kobbe, G; Nachtkamp, K	1
Astolfi, A; Boultwood, J; Casalin, I; Cavo, M; Cocco, L; De Stefano, A; Finelli, C; Follo, MY; Indio, V; Manzoli, L; McCubrey, JA; Mongiorgi, S; Paolini, S; Parisi, S; Pellagatti, A; Pession, A; Ratti, S; Suh, PG	1
Sallman, DA; Wang, C	1
Borthakur, G; Siddiqui, M	1
Cadeddu, RP; Christopeit, M; Drusenheimer, N; Esseling, E; Germing, U; Haas, R; Holtick, U; Jäger, P; Klein, S; Kobbe, G; Kröger, N; Mikesch, JH; Rautenberg, C; Scheid, C; Schroeder, T; Stelljes, M; Trenschel, R	1
Garcia-Manero, G	3
Aoki, Y; Minehata, K; Motegi, Y; Uno, S	1
Park, S	1
Al-Harbi, S; Lucero, J; Yee, KWL	1
Furihata, H; Imai, Y; Kosako, H; Miyakawa, T; Nagaoka, K; Nagasaka, T; Nishino, K; Sawasaki, T; Shibata, N; Shoya, Y; Tanokura, M; Taya, A; Usui, M; Yamanaka, S; Yanagihara, Y; Yoshida, S	1
Abou Dalle, I; Bannon, SA; Bhalla, K; DiNardo, CD; Garcia-Manero, G; Hu, S; Kanagal-Shamanna, R; Kantarjian, H; Patel, KP; Routbort, M	1
Ades, L; Fenaux, P; Platzbecker, U	1
Paumgartten, FJR	1
Casadevall, N; Gerds, AT; Kelaidi, C; Meunier, M; Park, S; Platzbecker, U	1
Steensma, DP	1
Patel, BJ; Sekeres, MA	1
A von dem Borne, P; Bargetzi, M; Biemond, BJ; Breems, DA; Chalandon, Y; Cloos, J; de Jongh, E; de Weerdt, O; Deeren, D; Fehr, M; Gjertsen, B; Graux, C; Huls, G; Janssen, JJJW; Jaspers, A; Jongen-Lavrencic, M; Klein, SK; Löwenberg, B; Maertens, J; Manz, M; Michaux, L; Ossenkoppele, GJ; Pabst, T; Stuessi, G; Tick, L; Valk, P; van der Klift, M; van der Poel, MWM; van der Velden, WJFM; van Marwijk Kooy, M; van Norden, Y; van Rhenen, A; Vekemans, MC	1
Almeida, A; Beach, CL; Fenaux, P; Giagounidis, A; Santini, V; Skikne, B; Tu, N; Weaver, J	1
Gore, S; Gorshein, E; Weber, UM	1
Bewersdorf, JP; Zeidan, AM	1
Adema, V; Alvarez, S; Benito, R; Diez-Campelo, M; Fenaux, P; Fontenay, M; Fuster-Tormo, F; Hernandez-Sanchez, JM; Ibañez, M; Kosmider, O; Larrayoz, MJ; Maciejewski, JP; Maietta, P; Neef, A; Palomo, L; Salgado, R; Sole, F; Such, E; Toma, A; Xicoy, B	1
Deng, Y; Docking, TR; Fuller, M; Gharaee, N; Hellström-Lindberg, E; Jädersten, M; Jiang, J; Karsan, A; Kulasekararaj, A; Li, J; List, AF; Malcovati, L; Martinez-Høyer, S; Mo, A; Parker, J; Platzbecker, U; Umlandt, P	1
Menssen, AJ; Walter, MJ	1
Dou, A; Fang, J; Feng, S; Halene, S; Hawkins, C; He, X; Lawley, L; Mizukawa, B; Patel, A; Roman-Rivera, A; Wunderlich, M; Zhang, J	1
Greenberg, P; Hellström-Lindberg, E; Tobiasson, M	1
Simon, JC; Treudler, R; Vucinic, V; Zader, J	1
Almeida, A; Beach, CL; Fenaux, P; Giagounidis, A; Haferlach, T; List, AF; MacBeth, KJ; Mavrommatis, K; Platzbecker, U; Santini, V; Wu, C; Zhong, J	1
Chen, J; Qin, TJ; Qu, SQ; Xiao, ZJ; Xu, ZF	1
Carraway, HE; Saygin, C	1
Avilés, A; Candelaria, M; Fabian-Morales, E; Gutierrez, O; Palacios-Campos, A	1
Altman, JK; Artz, AS; Bennett, JM; Cheema, PS; Claxton, DF; Komrokji, RS; List, AF; Litzow, MR; Luger, SM; Maciejewski, J; Mattison, RJ; McGraw, K; Schiffer, CA; Sun, Z; Tallman, MS; Verma, A; Wassenaar, TR	1
Döhner, K; Gabdoulline, R; Ganser, A; Ganster, C; Germing, U; Göhring, G; Gutermuth, A; Haase, D; Haferlach, C; Haferlach, T; Heuser, M; Kandziora, C; Klement, P; Klesse, S; Kobbe, G; Koenecke, C; Kröger, N; Krönke, J; Kubasch, AS; Meggendorfer, M; Mies, A; Panagiota, V; Platzbecker, U; Schiller, J; Schlegelberger, B; Schroeder, T; Shahswar, R; Shirneshan, K; Sperr, WR; Thiede, C; Thol, F; Valent, P	1
Bewersdorf, JP; Gore, SD; Huntington, SF; Ma, X; Podoltsev, NA; Wang, R; Wang, X; Zeidan, AM; Zhang, C	1
Bug, G; Büsche, G; Fey, S; Germing, U; Giagounidis, A; Götze, KS; Haase, D; Haferlach, T; Hecht, A; Hofmann, WK; Jann, JC; Letsch, A; Lübbert, M; Metzgeroth, G; Meyer, JA; Müller, N; Nolte, F; Nowak, D; Nowak, V; Obländer, J; Reinwald, M; Schafhausen, P; Schlenk, RF; Schuler, E; Sockel, K; Thol, F	1
Belli, CB; Larripa, IB; Lincango Yupanki, M; Metrebian, F; Narbaitz, M; Rahhal, M; Rocca, GS; Sarmiento, M; Zubieta, M	1
Al Ali, N; Basiorka, AA; Fenaux, P; Fontenay, M; Komrokji, R; Kosmider, O; Lancet, JE; List, AF; McGraw, KL; McLemore, AF; Padron, E; Sallman, DA; Wang, C	1
Azevedo, RS; Bassolli, L; Belli, C; Buccheri, V; Castelli, JB; Enrico, A; Ferri, L; Junior, W; Magalhaes, SM; Pereira, T; Perusini, MA; Pinheiro, RF; Rocha, V; Schuster, S; Traina, F; Velloso, E	1
Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E	1
Bacher, U; Braulke, F; Brümmendorf, TH; Bug, G; Büsche, G; Ganser, A; Germing, U; Giagounidis, A; Götze, K; Haas, R; Haase, D; Hofmann, WK; Letsch, A; Lübbert, M; Nolte, F; Platzbecker, U; Schafhausen, P; Schanz, J; Schlenk, RF; Schuler, E; Schulz, X; Shirneshan, K; Trümper, L	1
Blijlevens, NMA; Cermak, J; Chiba, K; da Silva-Coelho, P; de Graaf, AO; de Witte, T; Dugas, M; Huls, G; Jansen, JH; Knops, R; Koorenhof-Scheele, TN; Kroeze, LI; Massop, M; Miyano, S; Muus, P; Ogawa, S; Sandmann, S; Shiraishi, Y; Stevens-Kroef, MJ; Tanaka, H; van de Locht, LT; van der Reijden, BA; Yoshida, K	1
Appelbaum, FR; Atallah, E; Attar, EC; Bloomfield, CD; Buckstein, R; Cook, EK; Cull, AH; Erba, HP; Fang, M; Gaur, R; Gore, SD; List, AF; Litzow, MR; Moseley, A; Nazha, A; Odenike, O; Othus, M; Rauh, MJ; Roulston, D; Sekeres, MA; Stone, RM; Velasco, MR; Zhang, Y	1
An, J; Donovan, KA; Fischer, ES; Ponthier, CM; Sack, R; Seebacher, J; Stadler, MB	1
Craddock, C	1
Bug, G; Fabarius, A; Fey, S; Ganser, A; Germing, U; Giagounidis, A; Götze, K; Haase, D; Haferlach, C; Hofmann, WK; Jann, JC; Letsch, A; Lübbert, M; Mossner, M; Nolte, F; Nowak, D; Nowak, V; Obländer, J; Palme, I; Platzbecker, U; Pressler, J; Schlenk, R; Xanthopoulos, C	1
Beyne-Rauzy, O; Deeg, HJ; Del Cañizo, C; Fenaux, P; Giagounidis, A; Greenberg, PL; Guerci-Bresler, A; Hellström-Lindberg, E; List, AF; Mittelman, M; Muus, P; Nimer, SD; Powell, BL; Sekeres, MA; Selleslag, D; Shammo, JM; Skikne, B; Yu, X	1
Miyazaki, Y	2
Chen, N; Connarn, JN; Gao, Y; Hwang, R; Palmisano, M	1
Bwire, R; Castaneda, C; Chan-Liston, M; Freeman, J; Hirsch, D; McWilliams, R; Mezo, M; Minton, N; Phillips, L; Sheehan, P	1
Binder, G; Broder, MS; Chang, E; Cogle, CR; McGuire, M; Papoyan, E; Reddy, SR	1
Cortelezzi, A; Fattizzo, B; Ferla, V; Fracchiolla, NS; Freyrie, A; Iurlo, A; Reda, G	1
List, A; Sallman, D; Talati, C	1
Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N	1
Thakral, B; Wang, SA	1
Becht, E; Boeva, V; Cagnard, N; Chapuis, N; Chesnais, V; Chevret, S; Dumont, F; Fenaux, P; Fontenay, M; Fridman, WH; Kerdivel, G; Kosmider, O; Rousseau, A; Toma, A	1
Ades, L; Auberger, P; Basiorka, AA; Cluzeau, T; Fenaux, P; Irvine, B; List, A; Maciejewski, J; Masala, E; McGraw, KL; Santini, V; Wei, S	1
Binder, G; DeZern, AE; McGuire, M; Ni, Q; Smith, BD	1
Giagounidis, A	2
Béné, MC; Cartron, G; Commes-Maerten, T; Delaunay, J; Eveillard, M; Flet, L; Gagez, AL; Godmer, P; Godon, C; Le Bris, Y; Lodé, L; Loirat, M; Luycx, O; Ménard, A; Pellat-Deceunynck, C; Peterlin, P; Richebourg, S; Soussi, T; Theisen, O; Villemagne, B	1
Almeida, A; Beach, CL; Castaneda, C; Fenaux, P; Garcia-Manero, G; Goldberg, SL; Gröpper, S; Jonasova, A; Santini, V; Vey, N; Zhong, J	1
Shallis, RM; Zeidan, AM	1
Almeida, A; Altincatal, A; Beach, CL; Buckstein, R; Fenaux, P; Giagounidis, A; Guo, S; Platzbecker, U; Santini, V; Wu, C	1
Abe, M; Arai, N; Ariizumi, H; Baba, Y; Fujiwara, S; Harada, H; Hattori, N; Kabasawa, N; Kawaguchi, Y; Murai, S; Nakamaki, T; Saito, B; Sasaki, Y; Shimada, S; Tsukamoto, H; Uto, Y; Yanagisawa, K	1
Ebert, BL; Fenaux, P; List, A	1
Arcioni, F; Covezzoli, A; Cundari, S; Di Battista, V; Mecucci, C; Roncadori, A; Tura, S	1
Belickova, M; Cmunt, E; Fuchs, O; Jonasova, A; Michalova, K; Minarik, L; Moudra, A; Neuwirtova, R; Polackova, H; Siskova, M; Stopka, T; Zemanova, Z	1
Abel, GA; Brunner, AM; Cronin, A; Fathi, AT; Graubert, T; Habib, AR; Steensma, DP; Stone, R; Weng, S	1
Kiselev, P; Ma, X; Scott, BL; Steensma, DP; Sugrue, MM; Swern, AS	1
Adams, DN; Carr, SA; Chen, M; Ebert, BL; Fink, EC; Guirguis, AA; Haldar, SD; Kennedy, JA; Liddicoat, B; Mani, DR; McConkey, M; Nguyen, AT; Svinkina, T; Udeshi, ND	1
Finke, CM; Gangat, N; Idossa, D; Ketterling, RP; Lasho, TL; Pardanani, A; Patnaik, MM; Tefferi, A	1
Fenaux, P; Giagounidis, A; Göhring, G; Li, JS; List, AF; Mittelman, M; Schlegelberger, B; Sekeres, MA; Selleslag, D; Sugrue, MM; Swern, AS	1
Al-Kali, A; Alkharabsheh, OA; Alkhateeb, HB; Begna, KH; Elliott, MA; Gangat, N; Hogan, WJ; Litzow, MR; Patnaik, MS; Saadeh, SS; Zblewski, DL	1
Ali, A; Montoro, J; Raza, A; Yerlikaya, A	1
Platzbecker, U; Sockel, K	1
Burgos, S; Fuente, L; Garcia-Manero, G; Jabbour, EJ; Kanagal-Shamanna, R; Mela-Osorio, MJ; Montalban-Bravo, G; Soltysiak, KA	1
Feinberg, B; Klink, AJ; McGuire, M; Zeidan, AM	1
Akyüz, N; Asemissen, AM; Binder, M; Bonzanni, N; Fuchs, P; Germing, U; Hofmann, WK; Jann, JC; Mährle, T; Nolte, F; Nowak, D; Simnica, D	1
Platzbecker, U	1
Almeida, A; Fenaux, P; Garcia-Manero, G; Gattermann, N; Giagounidis, A; Goldberg, SL; Ozawa, K; Santini, V; Weaver, J	1
Armstrong, RN; Bochicchio, MT; Boultwood, J; Cavo, M; Cocco, L; De Fanti, S; Finelli, C; Follo, MY; Gobbi, M; Luiselli, D; Manzoli, L; Martinelli, G; McCubrey, JA; Miglino, M; Mongiorgi, S; Parisi, S; Pellagatti, A; Ratti, S; Russo, D; Suh, PG	1
Al Ali, NH; Cogle, C; Komrokji, RS; Lancet, JE; Lis, AF; Padron, E; Sallman, D; Tinsley, S	1
Chisti, MM; Fennell, T; Sanders, DS	1
Abbasi, T; Abbott, D; Cogle, CR; Drusbosky, L; Fullerton, A; Gutman, JA; Hammes, A; Hemenway, G; Jordan, CT; Miltgen, N; Pollyea, DA; Schatz, D; Singh, NK; Smith, C; Stevens, B; Vali, S; Wei, Q; Winters, A	1
Cho, SH; Choi, CW; Choi, Y; Kim, H; Kim, I; Kim, KH; Kim, SY; Kim, YJ; Lee, HS; Lee, JH; Lee, WS; Moon, JH; Park, J; Shin, HJ	1
Kunacheewa, C; Owattanapanich, W; Thongthang, P; Ungprasert, P; Utchariyaprasit, E	1
Bewersdorf, JP; Stahl, M; Zeidan, AM	1
Adès, L; Alary, AS; Alsafadi, S; Bondu, S; Bouscary, D; Boussaid, I; Bousta, A; Cagnard, N; Cluzeau, T; Droin, N; Fontenay, M; Ganz, T; Guillonneau, F; Gyan, E; Houy, A; Hunault, M; Jung, G; Kaltenbach, S; Karim, Z; Kautz, L; Kosmider, O; Kubasch, AS; Lefebvre, T; Lefèvre, C; Margueron, R; Mayeux, P; Nemeth, E; Park, S; Perrier, P; Platzbecker, U; Puy, H; Rombaut, D; Rousseau, A; Santini, V; Stamatoullas, A; Stern, MH; Toma, A; Wassef, M; Winter, S	1
Gattermann, N; Germing, U; Kaivers, J; Kobbe, G; Kündgen, A; Schroeder, T	1
Alati, C; Alimena, G; Aloe Spiriti, MA; Balleari, E; Breccia, M; Cortelezzi, A; D'Errigo, MG; Finelli, C; Galimberti, S; Laganà, C; Latagliata, R; Morabito, F; Nobile, F; Oliva, EN; Palumbo, G; Poloni, A; Rodà, F; Sanpaolo, G; Specchia, G; Volpe, A	1
Ades, L; Bally, C; Chesnais, V; Dreyfus, F; Fenaux, P; Fontenay, M; Kaltenbach, S; Kosmider, O; Leschi, C; Park, S; Rouquette, A; Santini, V; Sardnal, V; Toma, A	1
Chang, C; He, Q; Li, X; Wu, L; Xu, F; Zhang, Z	1
Matsumura, I; Morita, Y; Tanaka, H	1
Adès, L; Fenaux, P	3
Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S	1
Alvarez, S; Arenillas, L; Calasanz, MJ; Cervera, J; Cigudosa, JC; Costa, D; Del Rey, M; Diez-Campelo, M; Florensa, L; González-Martínez, T; Hernández, JM; Ibáñez, M; Jerez, A; Larráyoz, MJ; Lumbreras, E; Maciejewski, J; Mallo, M; Marugán, I; Nomdedeu, M; Pedro, C; Solé, F; Such, E	1
Blau, IW; Böhme, A; Braulke, F; Brümmendorf, TH; Bug, G; Detken, S; Ganster, C; Germing, U; Giagounidis, AA; Götze, K; Haase, D; Hofmann, WK; Jentsch-Ullrich, K; Jung, K; Lübbert, M; Metz, M; Müller-Thomas, C; Ottmann, O; Pfeiffer, S; Platzbecker, U; Schafhausen, P; Schanz, J; Schlenk, RF; Schmidt, B; Seraphin, J; Shirneshan, K; Stadler, M; Trümper, L	1
Germing, U; Platzbecker, U	1
Bornhäuser, M; Brocard, B; Ehninger, G; Ferrer, RA; Hofbauer, LC; List, C; Mohr, B; Platzbecker, U; Rauner, M; Schmitz, M; Schönefeldt, C; Stiehler, M; Wehner, R; Wobus, M	1
Amrein, PC; Attar, EC; Ballen, KK; Deangelo, DJ; Fathi, AT; Foster, J; Fraser, JW; McAfee, S; Neuberg, D; Steensma, DP; Stone, RM; Wadleigh, M	1
Scott, LJ; Syed, YY	1
Baer, MR; Davidoff, AJ; Gore, SD; Hendrick, F; Mahmoud, D; McNally, DL; Zeidan, AM	1
Cuzzola, M; Gentile, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E	1
Fenaux, P; Germing, U; Giagounidis, A; List, A; MacBeth, KJ; Mufti, GJ	1
Al Ali, NH; Basiorka, A; Boultwood, J; Caceres, G; Daugherty, FJ; Fulp, WJ; Johnson, J; Komrokji, RS; Lee, JH; List, AF; Littleton, N; Liu, K; McGraw, K; Pellagatti, A; Smith, LJ; Sokol, L; Wei, S; Wells, RA; Yip, BH; Zhang, L; Zhang, LM	1
Bennett, JM; Fu, T; Giagounidis, A; Knight, RD; List, AF; Nimer, SD; Sekeres, MA; Shammo, JM; Skikne, B	1
Gattermann, N; Germing, U; Haas, R; Kobbe, G	1
Ardanaz, MT; Arrizabalaga, B; Azaceta, G; Bargay, J; Cabrero, M; Calabuig, M; Cedena, T; Cerveró, C; Collado, R; del Cañizo, C; Díez-Campelo, M; García, M; Luño, E; Morell, MJ; Muñoz, JA; Nomdedeu, B; Pedro, C; Rodríguez, MJ; Rojas, SM; Simiele, A; Xicoy, B	1
Kharfan-Dabaja, MA; Komrokji, RS; Zeidan, AM	1
Ishikawa, T	2
Kuendgen, A	1
Tohyama, K	2
Ebert, BL; Komrokji, RS; List, AF; Padron, E	1
Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Tarakuwa, T	1
Besa, EC; Gaballa, MR	1
Bhagat, T; Braunschweig, I; Roth, M; Schinke, C; Steidl, U; Tamari, R; Verma, A; Will, B	1
Arilla, MJ; Arrizabalaga, B; Azaceta, G; Bailén, A; Bargay, J; Brunet, S; Cerveró, C; de Paz, R; Del Cañizo, C; Diez-Campelo, M; Falantes, J; García-Pintos, M; Lorenzo, I; Luño, E; Marco-Betes, V; Nomdedeu, B; Osorio, S; Ramos, F; Sánchez-García, J; Sanz, GF; Serrano-López, J; Such, E; Tormo, M; Valcárcel, D; Xicoy, B	1
Kanz, L; Weisel, K	1
Benettaib, B; Beyne-Rauzy, O; Bowen, D; del Cañizo, C; Fenaux, P; Fu, T; Ganser, A; Giagounidis, A; Göhring, G; Guerci-Bresler, A; Hellström-Lindberg, E; Lübbert, M; Mittelman, M; Mufti, GJ; Muus, P; Nilsson, L; Platzbecker, U; Quesnel, B; Sanz, G; Schlegelberger, B; Selleslag, D; te Boekhorst, P	1
Buckstein, R; Chesney, A; Cheung, M; Chodirker, L; Cussen, MA; Davidson, C; Kerbel, R; Lee, CR; Lenis, M; Mamedov, A; Reis, M; Shaked, Y; Wells, RA; Zhang, L	1
Schleiffenbaum, BE	1
Abe, Y; Hamano, A; Hattori, Y; Miyazaki, K; Nakagawa, Y; Sekine, R; Shingaki, S; Suzuki, K; Tsukada, N	1
Abe, T; Fujii, S; Fujita, M; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Matsuno, T; Nagashima, K; Sakurai, T; Sato, M; Yamada, M; Yoshida, M	1
Kizaki, M	1
Duong, VH; Komrokji, RS; List, AF	1
Alfinito, F; Avilia, S; Catalano, L; Cerchione, C; Cerciello, G; Pane, F; Picardi, M; Pisano, I; Risitano, AM	1
Bennett, JM; Dreyfus, F; Fenaux, P; Greenberg, PL; Li, JS; List, AF; Sanz, GF; Sekeres, MA; Sugrue, MM; Swern, AS	1
Meers, S	1
Dimopoulos, MA; Dispenzieri, A; Gertz, MA; Kastritis, E; Kumar, S; Orlowski, R; Shah, J; Shah, RA; Terpos, E	1
Bokorova, R; Brezinova, J; Cermak, J; Cervinek, L; Fuchs, O; Hajkova, H; Jonasova, A; Kostecka, A; Michalova, K; Mikulenkova, D; Neuwirtova, R; Polak, J; Siskova, M; Sponerova, D; Vostry, M	1
Belickova, M; Cermak, J; Hrustincova, A; Jonasova, A; Klema, J; Krejcik, Z; Merkerova, MD; Michalova, K; Stara, E; Zemanova, Z	1
Usuki, K	1
Bornhäuser, M; Ehninger, G; Kramer, M; Mohr, B; Oelschlaegel, U; Parmentier, S; Platzbecker, U; Sockel, K; Thiede, C; van de Loosdrecht, AA; Westers, TM	1
Basiorka, AA; Caceres, G; Clark, J; Heaton, R; Johnson, JO; List, AF; McGraw, KL; Ozawa, Y; Padron, E; Sokol, L; Wei, S	1
Klimek, V	1
Mukherjee, S; Ornstein, MC; Sekeres, MA	1
Bellotti, D; Boiocchi, L; Borlenghi, E; Cerqui, E; Imberti, L; Lamorgese, C; Pagani, C; Pelizzari, A; Rossi, G; Schieppati, F; Sottini, A	1
Beličková, M; Čermák, J; Dostálová Merkerová, M; Hruštincová, A; Jonášová, A; Kléma, J; Krejčík, Z; Michalová, K; Zemanová, Z	1
Patnaik, MM; Tefferi, A	1
Breccia, M; Carmosino, I; Finsinger, P; Latagliata, R; Mancini, M; Montagna, C; Oliva, E; Roberto, A; Romano, A; Volpicelli, P; Vozella, F	1
Champlin, RE; Pingali, SR	1
Barančik, M; Breier, A; Gibalová, L; Jonášová, A; Messingerová, L; Poleková, L; Šereš, M; Sulová, Z	1
Ali, A; Itzykson, R; Loiseau, C	1
Bullinger, L; Carr, SA; Cathers, BE; Chamberlain, PP; Chopra, R; Ebert, BL; Fink, EC; Gandhi, AK; Griffiths, E; Hollenbach, PW; Hurst, SN; Järås, M; Krönke, J; MacBeth, KJ; Man, HW; Mani, DR; McConkey, M; Schneider, RK; Svinkina, T; Udeshi, ND; Wetzler, M	1
Bieniaszewska, M; Butrym, A; Kumiega, B; Lech-Maranda, E; Madry, K; Mazur, G; Mital, A; Patkowska, E; Rybka, J; Torosian, T; Warzocha, K; Wichary, R	1
Braulke, F; Ganster, C; Haase, D; Platzbecker, U; Salinas-Riester, G; Schanz, J; Shirneshan, K	1
Al, MJ; Armstrong, N; Blommestein, HM; Deshpande, S; Kleijnen, J; Noake, C; Riemsma, R; Ryder, S; Severens, JL; Worthy, G	1
Berube, C; Cardone, MH; Coutre, S; Doykan, C; Garcia, JS; Gotlib, J; Greenberg, P; Hewitt, R; Liedtke, M; McMillan, A; Medeiros, BC; Narayan, R; Percival, ME; Regan, K; Williamson, C	1
Alati, C; Aloe Spiriti, MA; Balleari, E; Cortelezzi, A; D'Errigo, MG; Germing, U; Kündgen, A; Latagliata, R; Lauseker, M; Oliva, EN; Palumbo, GA; Poloni, A; Ricco, A; Ronco, F; Sanpaolo, G; Santacaterina, I; Volpe, A	1
Aschauer, G; Burgstaller, S; Fiegl, M; Fridrik, M; Girschikofsky, M; Greil, R; Keil, F; Linkesch, W; Nösslinger, T; Petzer, A; Stauder, R	1
Ebert, BL; Fink, EC	1
Al Ali, NH; Komrokji, RS; Lancet, J; List, A; Padron, E; Zeidan, AM	1
Burgstaller, S; Stauder, R; Wiesinger, P	1
Banos, A; Benramdane, R; Beyne-Rauzy, O; Bordessoule, D; Bouabdallah, K; Caillot, D; Chevret, S; Cheze, S; Chouffi, B; Cony-Makhoul, P; De Renzis, B; Delaunay, J; Dreyfus, F; Fenaux, P; Fontenay, M; Gardin, C; Gruson, B; Guerci-Bresler, A; Guilhot, F; Gyan, E; Isnard, F; Kosmider, O; Laribi, K; Legros, L; Lejeune, J; Maloum, K; Nimuboma, S; Petit, R; Preudhomme, C; Renneville, A; Rose, C; Salanoubat, C; Sanhes, L; Sardnal, V; Slama, B; Soussain, C; Stamatoullas, A; Taksin, AL; Tertian, G; Toma, A; Wattel, E; Wickenhauser, S	1
Komrokji, RS; List, AF	4
Ebert, BL; Guirguis, AA	1
Beyne-Rauzy, O; Chesnais, V; Chevret, S; Delaunay, J; Dreyfus, F; Dumont, F; Fenaux, P; Fontenay, M; Kosmider, O; Lambert, J; Lejeune, J; Passet, M; Preudhomme, C; Raimbault, A; Renneville, A; Rose, C; Solary, E; Stamatoullas, A; Toma, A	1
DeZern, AE	1
Bacher, U; Braulke, F; Bug, G; Büsche, G; Ganser, A; Gattermann, N; Germing, U; Giagounidis, A; Götze, K; Haas, R; Haase, D; Letsch, A; Lübbert, M; Nolte, F; Platzbecker, U; Schafhausen, P; Schlenk, RF; Schuler, E; Shirneshan, K; Wulfert, M	1
Buckstein, R; Rezmovitz, J; Wells, RA	1
Beličková, M; Bělohlávková, P; Čermák, J; Černá, O; Červinek, L; Hochová, I; Janoušová, E; Jonášová, A; Kačmářová, K; Rohoň, P; Šišková, M	1
Al Ali, NH; Bart-Smith, E; Craig, BM; Epling-Burnette, PK; Komrokji, RS; Kordasti, S; Kulasekararaj, A; Lancet, JE; List, AF; Mufti, GJ; Padron, E; Pinilla-Ibarz, J; Zhang, L	1
Al Ali, NH; Dalton, W; Fisher, K; Fulp, W; Hampras, SS; Kenvin, L; Knight, R; Komrokji, RS; Lancet, J; Lee, JH; List, A; Olesnyckyj, M; Padron, E; Rollison, DE; Shain, KH; Xu, Q	1
Cashen, AF; Cherian, MA; DiPersio, JF; Fiala, M; Fletcher, T; Gao, F; Jacoby, MA; Stockerl-Goldstein, K; Tibes, R; Uy, GL; Vij, R; Westervelt, P	1
Braulke, F; Bug, G; Büsche, G; Fey, S; Ganser, A; Germing, U; Giagounidis, A; Götze, K; Haase, D; Haferlach, T; Hofmann, WK; Jann, JC; Lauinger-Lörsch, E; Letsch, A; Lübbert, M; Metzgeroth, G; Mossner, M; Müller, N; Nolte, F; Nowak, D; Nowak, V; Obländer, J; Platzbecker, U; Pressler, J; Schafhausen, P; Schlenk, RF; Schuler, E; Shirneshan, K; Weiß, C	1
Barker, B; Bolanos, L; Cortelezzi, A; Cuzzola, M; Fang, J; Fontanillo, C; Grimes, HL; Komurov, K; Liu, X; MacBeth, K; Oliva, EN; Rigolino, C; Starczynowski, DT	1
Bassermann, F; Eichner, R; Einsele, H; Fernández-Sáiz, V; Garz, AK; Germing, U; Götze, KS; Haass, C; Heider, M; Jacobs, L; Keller, U; Knop, S; Knorn, AM; Kuster, B; Langer, C; Lemeer, S; Peschel, C; Platzbecker, U; Rudelius, M; Schmid, B; Slawska, J; Targosz, BS; van Bebber, F	1
Almeida, A; Beach, CL; Buckstein, R; Del Cañizo, C; Fenaux, P; Gattermann, N; Giagounidis, A; Gröpper, S; Hoenekopp, A; Jonasova, A; MacBeth, KJ; Mittelman, M; Mufti, GJ; Ozawa, K; Platzbecker, U; Ram, R; Risueño, A; Santini, V; Séguy, F; Shpilberg, O; Vey, N; Zhong, J	1
Krönke, J; Lindner, S	1
Braester, A; Ellis, M; Filanovsky, K; Goldschmidt, N; Herishanu, Y; Kirgner, I; Mittelman, M; Ofran, Y; Oster, HS; Perri, C; Raanani, P; Rosenbaum, H	1
Adema, V; Clemente, MJ; Hirsch, C; Hosono, N; List, AF; Maciejewski, JP; Makishima, H; McGraw, KL; Nazha, A; Negoro, E; Polprasert, C; Przychodzen, B; Radivoyevitch, T; Santini, V; Sekeres, MA; Sole, F	1
Ball, B; Gore, SD; Prebet, T; Zeidan, A	1
Carraway, HE; DeZern, A; Gojo, I; Gore, SD; Smith, BD; Zeidan, AM	1
Deng, ZQ; He, PF; Lian, XY; Lin, J; Qian, J; Wen, XM; Xu, ZJ; Yang, L; Yao, DM; Zhang, ZH	1
Abbasi, T; Bejar, R; Chang, M; Cogle, CR; Drusbosky, L; Hawkins, KE; Kumar, A; Lamba, JK; Mallo, M; Martuscello, R; Medina, C; Sekeres, MA; Singh, NK; Sole, F; Vali, S	1
Boultwood, J; Dimitriou, M; Douagi, I; Giai, V; Grandien, A; Hellström-Lindberg, E; Jacobsen, SE; Jädersten, M; Jansson, M; Karimi, M; LeBlanc, K; Neuberg, DS; Pellagatti, A; Saft, L; Scharenberg, C; Woll, PS	1
Santini, V	2
Carraway, HE	1
Ando, T; Kimura, S; Kizuka, H; Kojima, K; Kubota, Y; Kusaba, K; Nishioka, A; Sano, H; Shindo, T; Ureshino, H	1
Frederiksen, H; Marcher, CW; Mortensen, TB; Preiss, B	1
Al Ali, N; Cluzeau, T; Fenaux, P; Gore, SD; Komrokji, R; Park, S; Prebet, T; Sekeres, MA; Sugrue, MM; Toma, A; Vey, N	1
Stahl, M; Zeidan, AM	1
Ko, C; Leventhal, J; Much, M; Stahl, M; Weed, J; Witt, D; Zeidan, AM	1
Nohgawa, M; Oka, S; Ono, K	1
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A	1
Cazzola, M	1
Miyazawa, K	1
Cosler, LE; Ferro, SA; Greenberg, PL; Lyman, GH	1
Adès, L; Beyne-Rauzy, O; Boehrer, S; Burcheri, S; Chaury, MP; Delaunay, J; Dreyfus, F; Fenaux, P; Gardin, C; Hoarau, N; Laurent, G; Legros, L; Mbida, RM; Prebet, T; Ravoet, C; Stamatoullas, A; Vey, N	1
Nomdedeu, B	1
Wiernik, PH	1
Mohamedali, A; Mufti, GJ	1
Giagounidis, AA; Knight, R; List, AF; Maciejewski, JP; Raza, A; Sekeres, MA; Wride, K	1
Bacher, U; Haferlach, C; List, A; Maciejewski, JP; Tiu, R	1
Stone, RM	2
Estey, E; Scott, BL	1
Hellström-Lindberg, E; Jädersten, M	1
Hanson, CA; Ketterling, RP; Knudson, RA; Mesa, RA; Schwager, S; Tefferi, A	1
Ehninger, G; Mohr, B; Oelschlaegel, U; Platzbecker, U; Stewart, MM; Thiede, C	1
Brandenburg, NA; Bwire, R; Freeman, J; Knight, RD; Salomon, ML; Yang, X; Zeldis, JB	1
Garcia-Manero, G; Lyons, RM; Sekeres, M; Stone, R	1
Fenaux, P; Itzykson, R	1
Byrd, J; Chen, X; Dewald, G; Djeu, JY; Epling-Burnette, PK; Lawrence, N; List, A; Liu, Q; Maciejewski, J; Pireddu, R; Rocha, K; Sokol, L; Wei, S; Williams, A	1
Kurtin, SE; List, AF	1
Burkhard, R; Dürr, D; Hirschi, A; Honegger, H; Hummel, Y; O'Meara, A; Siciliano, RD	1
Chang, C; He, Q; Li, X; Wu, L; Xu, F; Zhang, Q; Zhang, Z	1
Erdel, M; Fiegl, M; Kilga-Nogler, S; Köck, L; Schennach, H; Sun, WL; Walder, A	1
Abruzzo, L; Borthakur, G; Bueso-Ramos, C; Faderl, S; Garcia-Manero, G; Issa, JP; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Shan, J	1
Galili, N; Raza, A	3
Harada, H; Kimura, A; Matsuda, A; Ozawa, K; Suzuki, K; Suzuki, T; Takatoku, M; Takeshita, K; Taniwaki, M; Tohyama, K; Tsudo, M; Watanabe, M; Yanagita, S; Yoshida, Y	1
Scott, BL	1
Galanopoulos, A; Giannikou, K; Hatzimichael, E; Kartasis, Z; Klaus, M; Kokoris, S; Korkolopoulou, P; Liapi, D; Papadaki, HA; Pappa, V; Parcharidou, A; Pontikoglou, C; Psyllaki, M; Sambani, C; Symeonidis, A; Ximeri, M	1
Gotlib, J; Greenberg, PL	1
List, A	1
Boultwood, J; Göhring, G; Hellström-Lindberg, E; Jädersten, M; Pellagatti, A; Porwit, A; Saft, L; Schlegelberger, B; Wainscoat, JS	1
Aul, C; Büsche, G; Giagounidis, A; Göhring, G; Hellström-Lindberg, E; Kreipe, HH; Schlegelberger, B; Zimmermann, M	1
Aprile, L; Bocchia, M; Chitarrelli, I; Defina, M; Fabbri, A; Gozzetti, A; Lauria, F; Rondoni, M	1
Bonkowski, J; Kolesar, JM; Vermeulen, LC	1
Sekeres, MA	1
Jain, P	1
Berzins, SP; Chan, AC; Godfrey, DI; Leeansyah, E; Neeson, P; Prince, HM; Quach, H; Ritchie, D; Tainton, K	1
Chen, W; Fan, L; Li, W; Liu, L; Liu, X; Xiong, B; Zou, P	1
Kishimoto, M; Kondo, T; Matsuoka, A; Nakahara, T; Tasaka, T; Tochigi, A; Tohyama, K; Tohyama, Y; Tsujioka, T	1
Dufva, IH; Risum, M	1
Alessandrino, PE; Angelucci, E; Barosi, G; Billio, A; Di Maio, M; Finelli, C; Locatelli, F; Marchetti, M; Morra, E; Musto, P; Santini, V; Tura, S; Visani, G	1
Carraway, HE; Gore, SD; Loaiza-Bonilla, A	1
Jädersten, M	1
Belkaid, M; Campo, E; Carrió, A; Costa, D; Coutinho, R; Muñoz, C; Nomdedeu, B; Vidal, A	1
Afable, M; Cuthbertson, D; Ganetsky, R; Ganetzky, R; Latham, D; List, AF; Loughran, TP; Maciejewski, JP; Paquette, R; Paulic, K; Saba, HI; Sekeres, MA	1
Clima, J; Galili, N; Quddus, F; Raza, A; Sajjad, G; Seedham, H	1
List, A; Sekeres, MA	2
Komrokji, RS; Lancet, JE; List, AF	1
Koppel, A; Schiller, G	1
Lachs, MS; Ritchie, EK	1
Sirulnik, LA; Stone, RM	1
Gotlib, J; Oh, ST	1
Alimena, G; Aloe Spiriti, MA; Breccia, M; Cortelezzi, A; Cuzzola, M; D'Errigo, MG; Finelli, C; Galimberti, S; Ghio, R; Iacopino, P; Laganà, C; Latagliata, R; Morabito, F; Nobile, F; Oliva, EN; Poloni, A; Ronco, F; Specchia, G	1
Hoffman, M; Mittelman, M; Neumann, D; Oster, HS	1
Bryan, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H; Prescott, H	1
Dumas, PY; Milpied, N; Pigneux, A; Tabrizi, R	1
Bardet, V; Dreyfus, F; Park, S; Vassilieff, D; Viguié, F	1
Bowen, DT; Chen, C; Giagounidis, AA; Haase, S; Schlegelberger, B; Wright, EG	1
Anderson, K; Astrand-Grundström, I; Buza-Vidas, N; Dhanda, RS; Ferry, H; Göhring, G; Hast, R; Hellström-Lindberg, E; Horvat, A; Jacobsen, SE; Johansson, B; List, A; Mead, AJ; Mizukami, T; Nilsson, L; Rydén, T; Schlegelberger, B; Strömbeck, B; Tehranchi, R; Vyas, P; Woll, PS	1
Hofmann, WK; Nolte, F	1
Azaceta, G; Bonafonte, E; Calasanz, MJ; Dourdil, V; Izquierdo, I; Palomera, L	1
Tefferi, A	1
Grivas, PD; Saloura, V	1
Carter, T; Chopra, R; Heise, C; Schafer, P	1
Büsche, G; Fenaux, P; Giagounidis, A; Göhring, G; Hellström-Lindberg, E; Hofmann, W; Kreipe, HH; Schlegelberger, B	1
Adamson, PC; Ayello, J; Berg, SL; Blaney, SM; Cairo, MS; Chen, N; Ingle, AM; Lau, H; Russell, H	1
Basinko, A; Berthou, C; Bovo, C; De Braekeleer, M; Douet-Guilbert, N; Eveillard, JR; Guéganic, N; Herry, A; Le Bris, MJ; Morel, F	1
Fenaux, P; Garcia-Manero, G	1
Alimena, G; Barzotti, R; Breccia, M; Cannella, L; Ferretti, A; Latagliata, R; Loglisci, G; Nanni, M; Oliva, EN; Santopietro, M	1
Jädersten, M; Karsan, A	1
Balin, SJ; Kurtin, PJ; Letendre, L; Pittelkow, MR; Wetter, DA	1
Bello, C; Komrokji, RS; Lancet, JE; List, AF; Wetzstein, GA; Yu, D; Zhu, W	1
Sanchez, JF	1
Komrokji, RS; List, AF; Sekeres, MA	1
Al-Shahrour, F; Dutt, S; Ebert, BL; Hurst, S; McAuley, JR; McConkey, M; Narla, A; Neuberg, D	1
Alimena, G; Breccia, M; Cannella, L; Carmosino, I; Cuzzola, M; Ferretti, A; Girmenia, C; Latagliata, R; Loglisci, G; Oliva, EN; Santopietro, M; Volpicelli, P; Vozella, F	1
Elloumi, M; Fenaux, P; Hadiji Mseddi, S; Jedidi, I; Kallel, F; Kassar, O; Sennana, H	1
Adès, L; Banos, A; Beyne-Rauzy, O; Blanc, M; de Botton, S; Delaunay, J; Delmer, A; Dreyfus, F; Eclache, V; Fenaux, P; Guerci, A; Kelaidi, C; Lamy, T; Le Bras, F; Rea, D; Schmidt, A; Sebert, M; Turlure, P; Vey, N; Visanica, S	1
Astermark, J; Dufva, IH; Dybedal, I; Ejerblad, E; Garelius, H; Grønbæk, K; Hellström-Lindberg, E; Jädersten, M; Jansson, M; Kjeldsen, L; Lindberg, EH; Linder, O; Möllgård, L; Nilsson, L; Nørgaard, JM; Porwit, A; Saft, L; Treppendahl, MB; Vestergaard, H	1
Aul, C; Beyne-Rauzy, O; Bowen, D; Cazzola, M; Del Cañizo, C; Fenaux, P; Francis, J; Fu, T; Ganser, A; Giagounidis, A; Guerci-Bresler, A; Hellström-Lindberg, E; Knight, R; Lübbert, M; Mittelman, M; Mufti, G; Muus, P; Nilsson, L; Platzbecker, U; Quesnel, B; Sanz, G; Schlegelberger, B; Selleslag, D; Te Boekhorst, P	1
Sekeres, MA; Tiu, RV	1
Aguilar, JL; Baumann, T; Calvo, X; Cervantes, F; Colomer, D; Costa, D; Díaz-Beyá, M; Esteve, J; Maffioli, M; Martínez-Trillos, A; Nomdedeu, B; Nomdedeu, M; Rozman, M	1
Büsche, G; Giagounidis, A; Göhring, G; Hellström-Lindberg, E; Hofmann, W; Kreipe, H; Lange, K; Morgan, M; Nielsen, KV; Roy, L; Schlegelberger, B	1
Katayama, Y	1
Gauthier, J; Leleu, X; Wémeau, M; Yakoub-Agha, I	1
Horiike, S; Kuroda, J; Nagoshi, H; Taniwaki, M	1
Cairoli, A; Voutsadakis, IA	1
Aul, C; Büsche, G; Germing, U; Giagounidis, AA; Göhring, G; Haase, S; Kulasekararaj, A; Mufti, GJ; Petersen, P; Platzbecker, U; Radkowski, R	1
Komrokji, R; List, AF; Padron, E	1
Adès, L; Banos, A; Blanc, M; Bouscary, D; Bresler, AG; Cabrol, MP; Chevret, S; Delaunay, J; Delmer, A; Dreyfus, F; Eclache, V; Fenaux, P; Kelaidi, C; Lamy, T; Le Bras, F; Sebert, M; Turlure, P; Vey, N; Visanica, S; Wattel, E	1
Gorin, NC; Isnard, F; Malak, S; Perot, C; Rubio, MT; Scherman, E	1
Aguayo, A; Armillas-Canseco, FM; Martínez-Baños, D	1
Altés, A; De Paz, R; del Cañizo, C; López Arrieta, JM	1
Fenaux, P; Freeman, J; Palumbo, A; Weiss, L	1
Bischoff, M	1
Landgren, O; Mailankody, S; Thomas, A	1
Harada, H; Jinnai, I; Kimura, A; Matsuda, A; Ozawa, K; Suzuki, K; Suzuki, T; Takatoku, M; Taniwaki, M; Tohyama, K; Tsudo, M; Watanabe, M; Yanagita, S; Yoshida, Y	1
Himmelmann, A; Tchinda, J	1
Chen, DT; Epling-Burnette, PK; Fulp, W; List, AF; McDaniel, JM; Zou, JX	1
Banos, A; Baracco, F; Besson, C; Blanc, M; Cannas, G; Corm, S; Fenaux, P; Perrier, H; Prebet, T; Sibon, D; Slama, B; Vey, N; Wattel, E	1
Akuthota, P; Kelly, E; Roberts, DH; Rosenthal, ES; Theisen-Toupal, J; Zwicker, JI	1
Afable, M; Guinta, K; Jankowska, A; Jerez, A; List, AF; Maciejewski, J; Makishima, H; McGraw, KL; O'Keefe, CL; Sekeres, MA; Sugimoto, Y; Szpurka, H; Tiu, R; Traina, F; Visconte, V	1
Jin, X; Zhang, YZ	1
Akpek, G; Brauer, DL; Edelman, B; Hess, JR; Rapoport, AP	1
Diez-Campelo, M; Giraldo, P; Hernández, MT; López-Corral, L; Matarraz, S; Mateos, MV; Orfao, A; Paiva, B; Pérez, E; San Miguel, JF	1
Billingsley, D; Caceres, G; Chen, X; Clark, J; Djeu, J; Eksioglu, EA; Epling-Burnette, PK; Fortenbery, N; Komrokji, R; Lancet, J; List, A; Maciejewski, JP; McGraw, K; Sallman, D; Sekeres, M; Sokol, L; Wang, H; Wei, S; Zhang, L; Zhou, J	1
Boccia, R; Brown, GL; Galili, N; Garcia-Manero, G; Lyons, RM; Mesa, RA; Mulford, D; Raza, A; Sekeres, MA; Smith, SE; Steensma, DP	1
Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A	1
Matsuoka, A; Tohyama, K; Tohyama, Y; Tsujioka, T	1
Borthakur, G; Chen, Y; Cortes, J; Estrov, Z; Faderl, S; Kantarjian, H; Ravandi, F; Rey, K	1
Belickova, M; Caniga, M; Cechova, E; Cermak, J; Dostalova Merkerova, M; Jonasova, A; Krejcik, Z; Michalova, K; Neuwirtova, R; Vesela, J; Votavova, H; Zemanova, Z	1
Somani, N	1
Cluzeau, T; Fenaux, P	1
Lentzsch, S; Pan, B	1
Brower, V	1
Buckstein, R; Leitch, HA; Shamy, A; Storring, JM	1
Advani, AS; Afable, M; Cuthbertson, D; Englehaupt, R; Jerez, A; Juersivich, J; Komrokji, R; Lancet, J; List, AF; Maciejewski, JP; Makishima, H; Paleveda, J; Paquette, R; Sekeres, MA; Tabarroki, A; Tiu, RV; Visconte, V	1
Caceres, G; Deeg, HJ; Karsan, A; List, AF; Nevill, TJ; Platzbecker, U; Scott, BL; Sokol, L; Sung, S; Venner, CP; Woltosz, JW	1
Chen, N; Komrokji, RS; Lancet, JE; List, AF; Lush, R; Paleveda, J; Saba, HI; Swern, AS	1
List, AF	6
Abouyahya, I; Alhan, C; Coenen, JL; de Kruijf, EJ; de Wolf, JT; Heyning, FH; Huls, GA; Imholz, AL; Kappers-Klunne, MC; Koedam, J; Koene, HR; Muus, P; Ossenkoppele, GJ; Planken, EV; Segeren, CM; te Boekhorst, PA; van de Loosdrecht, AA; van der Velden, AM; Vasmel, WL; Velders, GA; Veth, G; Westers, TM	1
Alimena, G; Aloe Spiriti, MA; Breccia, M; Cortelezzi, A; Cuzzola, M; Finelli, C; Galimberti, S; Ghio, R; Laganà, C; Latagliata, R; Morabito, F; Nobile, F; Oliva, EN; Palumbo, GA; Poloni, A; Ricco, A; Rigolino, C; Rodà, F; Sanpaolo, G; Volpe, A	1
Espinal-Witter, R; Geyer, JT; Knowles, DM; Mathew, S; Orazi, A; Racchumi, J; Subramaniyam, S; Verma, S; Wang, YL	1
Giagounidis, AA	1
Blaise, D; Charbonnier, A; Gelsi-Boyer, V; Mozziconacci, MJ; Prebet, T; Vey, N	1
Gandhi, S; Hu, K; Larson, RA; Liu, D; Lyons, RM; Matei, C; Scott, B; Wang, ES; Yang, AS	1
Dai, L; Gollin, SM; Lentzsch, S; Mapara, MY; Monaghan, SA; Normolle, DP	1
Rizzieri, DA	1
Backstrom, J; Brandenburg, NA; Fenaux, P; Germing, U; Giagounidis, AA; Glasmacher, A; Hasford, J; Kuendgen, A; Lauseker, M; List, AF	1
Brandenburg, NA; Fenaux, P; Knight, R; Muus, P; Revicki, DA; Yu, R	1
Bornhäuser, M; Braulke, F; Bug, G; Ehninger, G; Germing, U; Giagounidis, A; Götze, K; Haase, D; Hofmann, WK; Kündgen, A; Naumann, R; Neesen, J; Platzbecker, U; Röllig, C; Schönefeldt, C; Shirneshan, K; Wermke, M	1
Aul, C; Boultwood, J; Germing, U; Giagounidis, AA; Wainscoat, JS	1
Cazzola, M; Malcovati, L	1
Buresh, A; Fuchs, D; Heaton, R; Knight, R; Kurtin, S; List, A; Mahadevan, D; Rimsza, L; Roe, DJ; Zeldis, JB	1
Bauters, F; Berthon, C; Facon, T; Guieze, R; Kuhnovsky, F; Leleu, X; Micol, JB; Moreau, AS; Terriou, L; Yakoub-Agha, I	1
Aul, C; Germing, U; Giagounidis, AA; Heinsch, M; Hildebrandt, B; Strupp, C	1
Chng, WJ	1
Ganser, A; Stadler, M	1
Knight, R	1
Teo, SK	1
Bartlett, JB; Stirling, D; Tozer, A; Zeldis, JB	1
Hellström-Lindberg, E	1
Crane, E; List, A	1
Hammond, JM; Maier, SK	1
Nimer, SD	1
Fortenbaugh, C	1
Li, CY; Mesa, RA; Steensma, DP; Tefferi, A	1
Bennett, J; Dewald, G; Feldman, E; Giagounidis, A; Greenberg, P; Knight, R; List, A; Patin, J; Powell, B; Raza, A; Reeder, C; Schmidt, M; Stone, R; Thomas, D; Wride, K; Zeldis, J	1
Kale, V; List, AF	1
Aul, C; Giagounidis, AA; Göhring, G; Haase, S; Heinsch, M; Schlegelberger, B	1
Fenaux, P; Kelaidi, C	1
Le Beau, MM; Olney, HJ	1
Baker, AF; Bellamy, W; Green, S; List, AF	1
Goss, TF; Hellström-Lindberg, E; Jädersten, M; Knight, R; List, AF; Schaefer, C; Szende, A; Totten, PJ	1
Kurtin, S; Sokol, L	1
Kale, V; List, A; Melchert, M	1
Dimopoulos, MA; Kastritis, E	1
Steensma, DP; Tefferi, A	1
Deeg, HJ; Mhyre, AJ	1
Schiffer, CA	2
Baz, R; Kalmadi, S; Mahindra, A	1
List, A; Melchert, M; Williams, C	1
Kurtin, S	1
Shah, SR; Tran, TM	1
Snively, A	1
Oestreicher, P	1
Bennett, JM; Curtin, PT; Deeg, HJ; Dewald, GW; Dreisbach, L; Feldman, EJ; Greenberg, PL; Klimek, VM; Knight, RD; List, AF; Raza, A; Reeves, JA; Schiffer, CA; Schmidt, M; Shammo, JM; Stone, RM; Thomas, D; Wride, K; Zeldis, JB	1
List, A; Ortega, J	1
Sloand, EM	1
Garcia-Manero, G; Jagasia, M; Yang, AS	1
Eclache, V; Fenaux, P; Kelaidi, C	1
Bargou, R; Cosgrove, D; Einsele, H; Knop, S; List, A	1
Da Rocha, A; Eclache, V; Fenaux, P; Le Roux, G	1
Cripe, L; Fenaux, P; Giagounidis, A; Mufti, GJ; Muus, P; Platzbecker, U; Sanz, G; Von Lilienfeld-Toal, M; Wells, RA	1
Bosco, J; Ebert, BL; Galili, N; Golub, TR; Ladd-Acosta, C; Mak, R; Pretz, J; Raza, A; Stone, R; Tamayo, P; Tanguturi, S	1
Ohyashiki, K	1
Mitani, K	1

Reviews

135 review(s) available for lenalidomide and Myelodysplastic Syndromes

Article	Year
New Approaches to Myelodysplastic Syndrome Treatment. Current treatment options in oncology, 2022, Volume: 23, Issue:5 Topics: Anemia; Antineoplastic Agents; Azacitidine; Humans; Lenalidomide; Myelodysplastic Syndromes; Quality of Life	2022
Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML. Blood reviews, 2022, Volume: 56 Topics: Bortezomib; Deubiquitinating Enzymes; Drug Discovery; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Proteasome Endopeptidase Complex; Thalidomide; Ubiquitin	2022
SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes. Clinical lymphoma, myeloma & leukemia, 2023, Volume: 23, Issue:3 Topics: Anemia; Humans; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Risk Factors	2023
Myelodysplastic Syndromes: New Methods of Diagnosis, Prognostication, and Treatment Deutsches Arzteblatt international, 2023, 03-24, Volume: 120, Issue:12 Topics: Erythropoietin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Prognosis; Quality of Life	2023
Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes. Current treatment options in oncology, 2023, Volume: 24, Issue:5 Topics: Anemia; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life	2023
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. American journal of hematology, 2023, Volume: 98, Issue:8 Topics: Aged; Bone Marrow; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis	2023
[Treatment of lower risk myelodysplastic syndromes]. Bulletin du cancer, 2023, Volume: 110, Issue:11 Topics: Anemia; Hematinics; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk; Thrombocytopenia	2023
Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS). Current oncology (Toronto, Ont.), 2023, 06-27, Volume: 30, Issue:7 Topics: Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Prognosis; Risk	2023
How we manage adults with myelodysplastic syndrome. British journal of haematology, 2020, Volume: 189, Issue:6 Topics: Activin Receptors, Type II; Adult; Antilymphocyte Serum; Bridged Bicyclo Compounds, Heterocyclic; Erythrocyte Transfusion; Female; Humans; Immunoglobulin Fc Fragments; Lenalidomide; Male; Mutation; Myelodysplastic Syndromes; Recombinant Fusion Proteins; Sulfonamides	2020
The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. Annals of hematology, 2020, Volume: 99, Issue:1 Topics: Activin Receptors, Type II; Bone Marrow Cells; Erythropoietin; Female; Ferritins; Hemoglobins; Humans; Immunoglobulin Fc Fragments; Lenalidomide; Male; Myelodysplastic Syndromes; Prognosis; Recombinant Fusion Proteins; Risk Factors	2020
Does early diagnosis and treatment of myelodysplastic syndromes make a difference? Best practice & research. Clinical haematology, 2019, Volume: 32, Issue:4 Topics: Allografts; Azacitidine; Decitabine; Early Diagnosis; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk Factors	2019
Lowering the boom on lower-risk myelodysplastic syndromes. Hematology. American Society of Hematology. Education Program, 2019, 12-06, Volume: 2019, Issue:1 Topics: Activin Receptors, Type II; Aged; Antilymphocyte Serum; Benzoates; Bone Marrow Cells; Female; Hematinics; Humans; Hydrazines; Immunoglobulin Fc Fragments; Lenalidomide; Mutation; Myelodysplastic Syndromes; Pyrazoles; Recombinant Fusion Proteins; Risk Factors; Thrombocytopenia	2019
Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter? Expert review of hematology, 2020, Volume: 13, Issue:3 Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk Factors; Tumor Suppressor Protein p53	2020
Evolving therapies for lower-risk myelodysplastic syndromes. Annals of hematology, 2020, Volume: 99, Issue:4 Topics: Anemia; Blood Transfusion; Chelation Therapy; Clinical Trials as Topic; Cri-du-Chat Syndrome; Drugs, Investigational; Forecasting; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Iron Overload; Lenalidomide; Molecular Targeted Therapy; Multicenter Studies as Topic; Myelodysplastic Syndromes; Precision Medicine; Prognosis; Risk Assessment; Severity of Illness Index	2020
Genetics of progression from MDS to secondary leukemia. Blood, 2020, 07-02, Volume: 136, Issue:1 Topics: Cell Count; Clonal Evolution; Disease Progression; DNA Methylation; DNA Mutational Analysis; Epigenesis, Genetic; Exome Sequencing; Hematopoietic Stem Cells; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Myelopoiesis; Neoplastic Stem Cells; Prognosis; Tumor Burden; Whole Genome Sequencing	2020
Myelodysplastic syndromes: moving towards personalized management. Haematologica, 2020, Volume: 105, Issue:7 Topics: Anemia; Erythropoiesis; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	2020
[Lenalidomide for myelodysplastic syndrome with excess blasts with germline DDX41 mutation: a case report and literatures review]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2020, 10-14, Volume: 41, Issue:10 Topics: Blood Cell Count; DEAD-box RNA Helicases; Germ Cells; Germ-Line Mutation; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes	2020
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. Seminars in hematology, 2017, Volume: 54, Issue:3 Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2017
Thrombopoietin mimetics for patients with myelodysplastic syndromes. The Cochrane database of systematic reviews, 2017, 09-30, Volume: 9 Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin	2017
Current treatment algorithm for the management of lower-risk MDS. Hematology. American Society of Hematology. Education Program, 2017, 12-08, Volume: 2017, Issue:1 Topics: Algorithms; Allografts; Erythrocyte Transfusion; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide; Transforming Growth Factor beta	2017
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. Leukemia, 2018, Volume: 32, Issue:7 Topics: Animals; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Management; Disease Progression; Drug Development; Genetic Heterogeneity; Genetic Predisposition to Disease; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Prognosis; Treatment Outcome; Tumor Suppressor Protein p53	2018
Improving Treatment for Myelodysplastic Syndromes Patients. Current treatment options in oncology, 2018, 10-25, Volume: 19, Issue:12 Topics: Aging; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Enzyme Inhibitors; Humans; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation, Homologous	2018
Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide? Drugs, 2018, Volume: 78, Issue:18 Topics: Disease Progression; DNA Methylation; Humans; Immunotherapy; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Transplantation, Homologous	2018
Treatment of MDS. Blood, 2019, 03-07, Volume: 133, Issue:10 Topics: Disease Progression; Erythropoiesis; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Iron Chelating Agents; Lenalidomide; Methylation; Myelodysplastic Syndromes; Prognosis; Risk; Severity of Illness Index; Translational Research, Biomedical; Transplantation, Homologous	2019
A systematic review and meta Hematology (Amsterdam, Netherlands), 2019, Volume: 24, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Female; Hematologic Diseases; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome	2019
Novel therapies in low- and high-risk myelodysplastic syndrome. Expert review of hematology, 2019, Volume: 12, Issue:10 Topics: Activin Receptors, Type II; Anemia; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Erythrocyte Transfusion; Hematinics; Humans; Immunoglobulin Fc Fragments; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Oligonucleotides; Prognosis; Recombinant Fusion Proteins; Risk Assessment; Stem Cell Transplantation; Sulfonamides; Thalidomide; Thrombopoietin; Transplantation, Homologous	2019
How we treat lower-risk myelodysplastic syndromes. Blood, 2013, May-23, Volume: 121, Issue:21 Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk Factors; Thalidomide	2013
Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison? Leukemia, 2013, Volume: 27, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2013
Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion. Drugs, 2013, Volume: 73, Issue:11 Topics: Anemia; Anemia, Macrocytic; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome	2013
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Annals of hematology, 2014, Volume: 93, Issue:1 Topics: Angiogenesis Inhibitors; Apoptosis; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Clone Cells; Disease Progression; Erythropoiesis; Gene Dosage; Genes, Tumor Suppressor; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2014
Myelodysplastic syndromes: diagnosis, prognosis, and treatment. Deutsches Arzteblatt international, 2013, Nov-15, Volume: 110, Issue:46 Topics: Blood Transfusion; Combined Modality Therapy; Humans; Immunologic Factors; Incidence; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Risk Factors; Stem Cell Transplantation; Survival Rate; Thalidomide	2013
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Current opinion in hematology, 2014, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Methylation; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Prognosis; Recurrence; Retreatment; Thalidomide; Transplantation, Homologous; Treatment Failure; Treatment Outcome	2014
Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome. International journal of clinical oncology, 2014, Volume: 19, Issue:1 Topics: Azacitidine; Benzamides; Decitabine; DNA Methylation; Humans; Imatinib Mesylate; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Thalidomide	2014
[Myelodysplastic syndromes: treatment strategy up-to-date]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:1 Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles	2014
Deletion 5q MDS: molecular and therapeutic implications. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:4 Topics: Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythropoiesis; Haploinsufficiency; Humans; Lenalidomide; Megakaryocytes; MicroRNAs; Myelodysplastic Syndromes; Phenotype; Ribosomal Proteins; Thalidomide; Tumor Suppressor Protein p53	2013
der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases. Acta haematologica, 2014, Volume: 132, Issue:2 Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Banding; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 5; Contraindications; Fatal Outcome; Female; Hematologic Neoplasms; Humans; Karyotype; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Lymphoma, T-Cell, Peripheral; Male; Megakaryocytes; Myelodysplastic Syndromes; Neoplasms, Second Primary; Recurrence; Remission Induction; Thalidomide; Translocation, Genetic	2014
Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide. Annals of hematology, 2014, Volume: 93, Issue:5 Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Gene Expression; Haploinsufficiency; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; MicroRNAs; Myelodysplastic Syndromes; Practice Guidelines as Topic; Ribosomal Proteins; Thalidomide; Tumor Suppressor Protein p53	2014
Lenalidomide. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2014, Volume: 201 Topics: Animals; Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Thalidomide	2014
Update on the pharmacotherapy for myelodysplastic syndromes. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:13 Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Remission Induction; Risk Assessment; Thalidomide	2014
The myelodysplastic syndromes: the era of understanding. European journal of haematology, 2015, Volume: 94, Issue:5 Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Erythropoietin; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Neoplasm Proteins; Prognosis; Spliceosomes; Thalidomide; Transplantation, Homologous	2015
[Treatment of MDS]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Allografts; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Autografts; Azacitidine; Enzyme Inhibitors; Erythrocyte Transfusion; Erythropoietin; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Immunologic Factors; Immunosuppressive Agents; Induction Chemotherapy; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; Transplantation Conditioning	2014
More is better: combination therapies for myelodysplastic syndromes. Best practice & research. Clinical haematology, 2015, Volume: 28, Issue:1 Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progression; Drug Therapy, Combination; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines; Thalidomide; Valproic Acid; Vorinostat	2015
Refractory anemia with ring sideroblasts and RARS with thrombocytosis. American journal of hematology, 2015, Volume: 90, Issue:6 Topics: Anemia, Refractory; Anemia, Sideroblastic; Angiogenesis Inhibitors; Aspirin; Female; Humans; Iron Overload; Janus Kinase 2; Lenalidomide; Male; Mutation; Myelodysplastic Syndromes; Phosphoproteins; Platelet Aggregation Inhibitors; Receptors, Thrombopoietin; Ribonucleoprotein, U2 Small Nuclear; Risk Factors; RNA Splicing Factors; Thalidomide; Thrombocytosis	2015
Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. Bone marrow transplantation, 2015, Volume: 50, Issue:9 Topics: Allografts; Bortezomib; Chemoradiotherapy; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Transplantation Conditioning	2015
New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide. Experimental hematology, 2015, Volume: 43, Issue:8 Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Thalidomide; Translational Research, Biomedical	2015
Where Does Lenalidomide Fit in Non-del(5q) MDS? Current hematologic malignancy reports, 2015, Volume: 10, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 5; Combined Modality Therapy; Humans; Immunologic Factors; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Patient Selection; Thalidomide; Treatment Outcome	2015
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. American journal of hematology, 2015, Volume: 90, Issue:9 Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Disease Management; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Research Design; Thalidomide; Transplantation, Homologous	2015
The novel mechanism of lenalidomide activity. Blood, 2015, Nov-19, Volume: 126, Issue:21 Topics: Animals; Humans; Ikaros Transcription Factor; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Proteasome Endopeptidase Complex; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases	2015
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:1 Topics: Angiogenesis Inhibitors; Chromosome Deletion; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk; Thalidomide; Treatment Outcome	2016
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond. Current opinion in cell biology, 2015, Volume: 37 Topics: Angiogenesis Inhibitors; Animals; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Substrate Specificity; Thalidomide; Transcription, Genetic; Ubiquitination	2015
The molecular mechanism of thalidomide analogs in hematologic malignancies. Journal of molecular medicine (Berlin, Germany), 2016, Volume: 94, Issue:12 Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Casein Kinase I; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Interleukin-2; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Peptide Hydrolases; Protein Binding; Proteolysis; Signal Transduction; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination	2016
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. Leukemia & lymphoma, 2017, Volume: 58, Issue:5 Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; DNA Methylation; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Thalidomide; Treatment Outcome	2017
Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis. PloS one, 2016, Volume: 11, Issue:11 Topics: Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2016
Treatment of low-risk myelodysplastic syndromes. Hematology. American Society of Hematology. Education Program, 2016, Dec-02, Volume: 2016, Issue:1 Topics: Allografts; Blood Transfusion; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk Factors; Thalidomide	2016
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure. Hematology. American Society of Hematology. Education Program, 2016, Dec-02, Volume: 2016, Issue:1 Topics: Azacitidine; Drug Resistance; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2016
5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10). International journal of hematology, 2017, Volume: 105, Issue:5 Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 5; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Translocation, Genetic	2017
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. Cancer, 2017, 05-15, Volume: 123, Issue:10 Topics: Anemia; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 5; Disease Progression; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2017
[Novel medical treatment modalities in hematology]. Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24 Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine	2008
[Pathogenesis of and therapeutic progress for myelodysplastic syndromes]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2008, Volume: 49, Issue:10 Topics: Azacitidine; Clinical Trials as Topic; Decitabine; Deoxycytidine; DNA Methylation; Drug Design; Gene Targeting; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha	2008
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs). Current treatment options in oncology, 2009, Volume: 10, Issue:1-2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult	2009
Van-den Berghe's 5q- syndrome in 2008. British journal of haematology, 2009, Volume: 144, Issue:2 Topics: Antineoplastic Agents; Chromosomes, Human, Pair 5; Cytogenetics; Gene Deletion; Genes, Tumor Suppressor; Humans; Lenalidomide; Myelodysplastic Syndromes; Ribosomal Proteins; Thalidomide	2009
Are new agents really making a difference in MDS? Best practice & research. Clinical haematology, 2008, Volume: 21, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2008
Management of myelodysplastic syndromes: 2008 update. Oncology (Williston Park, N.Y.), 2008, Nov-15, Volume: 22, Issue:12 Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome	2008
Myelodysplastic syndromes: biology and treatment. Journal of internal medicine, 2009, Volume: 265, Issue:3 Topics: Antineoplastic Agents; Blood Transfusion; Chromosomes, Human, Pair 5; Disease Progression; Erythropoietin; Female; Humans; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Male; Myelodysplastic Syndromes; Recombinant Proteins; Sequence Deletion; Thalidomide; World Health Organization	2009
How I treat patients with myelodysplastic syndromes. Blood, 2009, Jun-18, Volume: 113, Issue:25 Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous	2009
Optimal sequencing of treatments for patients with myelodysplastic syndromes. Current opinion in hematology, 2009, Volume: 16, Issue:2 Topics: Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Transplantation, Homologous	2009
Novel biospecific agents for the treatment of myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network : JNCCN, 2003, Volume: 1, Issue:4 Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; Etanercept; Farnesyltranstransferase; Humans; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Oxides; Receptors, Tumor Necrosis Factor; Thalidomide	2003
Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes. Clinical lymphoma & myeloma, 2009, Volume: 9 Suppl 3 Topics: Antineoplastic Agents; Chromosome Deletion; Clinical Trials as Topic; Disease Progression; Humans; Immunosuppression Therapy; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Medical Oncology; Myelodysplastic Syndromes; Risk; Thalidomide; Treatment Outcome	2009
The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2010, Volume: 16, Issue:4 Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Costs; Drug Interactions; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide	2010
[Novel therapeutic agents for myelodysplastic syndrome]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:10 Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide	2009
Treatment of MDS: something old, something new, something borrowed... Hematology. American Society of Hematology. Education Program, 2009 Topics: Azacitidine; Benzoates; Blood Transfusion; Bone Marrow Diseases; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA-Cytosine Methylases; Glutathione; Hematinics; Humans; Hydrazines; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Risk; Thalidomide; Thrombopoietin	2009
Lenalidomide-induced acute liver failure. Blood transfusion = Trasfusione del sangue, 2009, Volume: 7, Issue:4 Topics: Adenine; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Hepatitis B, Chronic; Humans; Lenalidomide; Liver Failure, Acute; Male; Myelodysplastic Syndromes; Organophosphonates; Thalidomide	2009
Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents. Current opinion in hematology, 2010, Volume: 17, Issue:2 Topics: Antineoplastic Agents; Benzoates; Enzyme Inhibitors; Humans; Hydrazines; Lenalidomide; Methyltransferases; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Thalidomide; Treatment Outcome	2010
Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Hematology/oncology clinics of North America, 2010, Volume: 24, Issue:2 Topics: Aged; Anemia; Animals; Apoptosis; Blood Transfusion; Bone Marrow; cdc25 Phosphatases; Cell Nucleus; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Clone Cells; Combined Modality Therapy; Erythropoiesis; Forecasting; G2 Phase; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Rats; Receptors, Erythropoietin; Thalidomide	2010
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good? Current hematologic malignancy reports, 2006, Volume: 1, Issue:1 Topics: Blood Transfusion; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Immunologic Factors; Lenalidomide; Multicenter Studies as Topic; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome	2006
Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more? Current hematologic malignancy reports, 2010, Volume: 5, Issue:1 Topics: Anemia; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Clone Cells; Combined Modality Therapy; Disease Progression; Erythropoiesis; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Risk; Survival Analysis; Thalidomide	2010
Pharmacotherapy of myelodysplastic syndromes. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:11 Topics: Azacitidine; Decitabine; DNA Methylation; Drug Approval; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; United States; United States Food and Drug Administration	2010
The lower risk MDS patient at risk of rapid progression. Leukemia research, 2010, Volume: 34, Issue:12 Topics: Age Factors; alpha Catenin; Antigens, Differentiation; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Caspase 3; Chromosome Aberrations; Cyclin-Dependent Kinase Inhibitor p15; Cytokines; DNA Methylation; Erythrocyte Transfusion; Female; Ferritins; Fibrosis; Gene Expression Regulation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Inhibitor of Apoptosis Proteins; Lenalidomide; Leukocyte Count; Lipoproteins, LDL; Lymphoid Enhancer-Binding Factor 1; Male; Microtubule-Associated Proteins; Mutation; Myelodysplastic Syndromes; Platelet Count; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptor Protein-Tyrosine Kinases; Risk Factors; Sex Factors; Survivin; Thalidomide	2010
Current and future management options for myelodysplastic syndromes. Drugs, 2010, Jul-30, Volume: 70, Issue:11 Topics: Adenine Nucleotides; Anemia; Arabinonucleosides; Benzamides; Bone Marrow; Clofarabine; DNA Methylation; Drugs, Investigational; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Risk Factors; Thalidomide; Thrombopoietin	2010
[Current treatment options for myelodysplastic syndromes]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:38 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blood Transfusion; Bone Marrow Transplantation; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Iron Overload; Lenalidomide; Leukemia, Myeloid, Acute; Long-Term Care; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Thalidomide	2010
Lenalidomide: a synthetic compound with an evolving role in cancer management. Hematology (Amsterdam, Netherlands), 2010, Volume: 15, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Treatment Outcome	2010
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert review of anticancer therapy, 2010, Volume: 10, Issue:10 Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythropoiesis; Genes; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2010
Hypomethylating agents and other novel strategies in myelodysplastic syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Feb-10, Volume: 29, Issue:5 Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epoetin Alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Thalidomide; Transplantation, Homologous	2011
Treatment of myelodysplastic syndromes in elderly patients. Advances in therapy, 2011, Volume: 28 Suppl 2 Topics: Aged; Anemia, Macrocytic; Antineoplastic Agents; Azacitidine; Blood Component Transfusion; Case Management; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Contraindications; Hematinics; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunomodulation; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Risk Assessment; Survival Rate; Thalidomide	2011
Management of lower-risk myelodysplastic syndromes: the art and evidence. Current hematologic malignancy reports, 2011, Volume: 6, Issue:2 Topics: Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Thalidomide	2011
[Molecular mechanisms of lenalidomide for the treatment of myelodysplastic syndromes]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:7 Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Genes, p53; Haploidy; Humans; Lenalidomide; MicroRNAs; Molecular Targeted Therapy; Myelodysplastic Syndromes; Ribosomal Proteins; Thalidomide	2011
[IMiDs in hematology]. Bulletin du cancer, 2011, Volume: 98, Issue:8 Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Thalidomide; Waldenstrom Macroglobulinemia	2011
Cytogenetic and molecular abnormalities in myelodysplastic syndrome. Current molecular medicine, 2011, Volume: 11, Issue:8 Topics: Animals; Antineoplastic Agents; Azacitidine; Chromosome Aberrations; Humans; Lenalidomide; Mutation; Myelodysplastic Syndromes; Thalidomide	2011
Role of lenalidomide in the treatment of myelodysplastic syndromes. Seminars in oncology, 2011, Volume: 38, Issue:5 Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia	2011
Treatment of higher-risk myelodysplastic syndrome. Seminars in oncology, 2011, Volume: 38, Issue:5 Topics: Algorithms; Antineoplastic Agents; Azacitidine; Combined Modality Therapy; Decitabine; DNA Methylation; Drug Therapy, Combination; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Myelodysplastic Syndromes; Patient Selection; Stem Cell Transplantation; Thalidomide	2011
A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes. Leukemia & lymphoma, 2012, Volume: 53, Issue:5 Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Haploinsufficiency; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2012
[Novel therapeutics for myelodysplastic syndromes]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:10 Topics: Azacitidine; Decitabine; DNA Methylation; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2011
Antiangiogenesis in myelodysplastic syndrome. Current cancer drug targets, 2011, Volume: 11, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Receptors, Vascular Endothelial Growth Factor; Thalidomide	2011
The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes. Expert opinion on drug safety, 2012, Volume: 11, Issue:1 Topics: Administration, Oral; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Product Surveillance, Postmarketing; Renal Insufficiency; Thalidomide; Time Factors	2012
Immunomodulating drugs in myelodysplastic syndromes. Hematology. American Society of Hematology. Education Program, 2011, Volume: 2011 Topics: Chromosome Deletion; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Risk Factors; Thalidomide	2011
[MDS]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:1 Topics: Azacitidine; Benzoates; Clinical Trials as Topic; Cytokines; Deferasirox; Drug Therapy, Combination; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Thrombopoietin; Treatment Outcome; Triazoles	2012
[Lenalidomide in hematological malignancies---review]. Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:1 Topics: Angiogenesis Inhibitors; Hematologic Neoplasms; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide	2012
Lenalidomide for treatment of myelodysplastic syndromes. Current pharmaceutical design, 2012, Volume: 18, Issue:22 Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2012
Approach to new therapeutics: investigation by the use of MDS-derived cell lines. Current pharmaceutical design, 2012, Volume: 18, Issue:22 Topics: Animals; Cell Line; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Profiling; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide	2012
Myelodysplastic syndromes: a challenging disease for patients and physicians. The Journal of the Association of Physicians of India, 2012, Volume: 60 Topics: Antineoplastic Agents; Blood Transfusion; Cytogenetics; Hematinics; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Stem Cell Transplantation; Thalidomide	2012
[New tools and treatments in myelodysplastic syndromes]. La Revue de medecine interne, 2013, Volume: 34, Issue:3 Topics: Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Cytogenetics; Decitabine; Flow Cytometry; Gene Expression Profiling; Humans; Immunologic Factors; Lenalidomide; Mutation; Myelodysplastic Syndromes; Prognosis; Thalidomide	2013
The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacology & therapeutics, 2012, Volume: 136, Issue:1 Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide	2012
The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline. Critical reviews in oncology/hematology, 2013, Volume: 85, Issue:2 Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Immunologic Factors; Karyotype; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Thalidomide	2013
New therapeutics for myelodysplastic syndromes. Leukemia research, 2012, Volume: 36, Issue:12 Topics: Antineoplastic Agents; Azacitidine; Bone Marrow; Chromosomes, Human, Pair 5; Glycine; Humans; Hydroxamic Acids; Lenalidomide; Myelodysplastic Syndromes; Neoplastic Stem Cells; p38 Mitogen-Activated Protein Kinases; Sequence Deletion; Sulfones; Thalidomide; Transforming Growth Factor beta; Tumor Microenvironment	2012
Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes. Seminars in hematology, 2012, Volume: 49, Issue:4 Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2012
Novel therapeutic strategies: hypomethylating agents and beyond. Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Aged; Aged, 80 and over; Algorithms; Cell Transformation, Neoplastic; Comorbidity; Cytogenetics; DNA Methylation; Erythropoiesis; Hematology; Humans; Immunosuppressive Agents; Karyotyping; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Remission Induction; Thalidomide; Treatment Outcome	2012
[Thalidomide: mechanisms of action and new insights in hematology]. La Revue de medecine interne, 2005, Volume: 26, Issue:2 Topics: Amyloidosis; Angiogenesis Inhibitors; Clinical Trials as Topic; Cytokines; Follow-Up Studies; Forecasting; Hematologic Diseases; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrence; Thalidomide; Time Factors; Waldenstrom Macroglobulinemia	2005
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good? Current hematology reports, 2005, Volume: 4, Issue:3 Topics: Aged; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cytokines; Female; Hematologic Diseases; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2005
Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS). Seminars in oncology, 2005, Volume: 32, Issue:4 Suppl 5 Topics: Chromosome Aberrations; Erythroid Cells; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2005
IMiDs: a novel class of immunomodulators. Seminars in oncology, 2005, Volume: 32, Issue:4 Suppl 5 Topics: Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide	2005
Properties of thalidomide and its analogues: implications for anticancer therapy. The AAPS journal, 2005, Mar-22, Volume: 7, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Cell Adhesion Molecules; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Drug Screening Assays, Antitumor; Endothelium, Vascular; Humans; Immunologic Factors; Interferon-gamma; Interleukin-2; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; T-Lymphocyte Subsets; Thalidomide	2005
Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. British journal of cancer, 2005, Sep-19, Volume: 93, Issue:6 Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide	2005
Immunomodulatory drugs. Cancer investigation, 2005, Volume: 23, Issue:7 Topics: Humans; Immunosuppressive Agents; Interleukin-12; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Multiple Myeloma; Myelodysplastic Syndromes; Neovascularization, Pathologic; T-Lymphocytes; Thalidomide	2005
Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome. The Annals of pharmacotherapy, 2006, Volume: 40, Issue:2 Topics: Animals; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; MEDLINE; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide	2006
Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16 Topics: Anemia, Hypochromic; Azacitidine; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Erythropoiesis; Erythropoietin; Gene Deletion; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Thalidomide	2006
Immunomodulatory drugs in myelodysplastic syndromes. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Apoptosis; Blood Transfusion; Cell Lineage; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Cytokines; Drug Evaluation, Preclinical; Drugs, Investigational; Erythrocyte Transfusion; Erythropoiesis; Female; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; NF-kappa B; Pilot Projects; Thalidomide; Thrombocytopenia; Tumor Necrosis Factor-alpha	2006
MDS: navigating the complex course. ONS news, 2006, Volume: 21, Issue:8 Suppl Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Immunosuppressive Agents; Lenalidomide; Medical History Taking; Myelodysplastic Syndromes; Neoplasm Staging; Nurse's Role; Nursing Assessment; Oncology Nursing; Physical Examination; Thalidomide	2006
Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes. Current pharmaceutical biotechnology, 2006, Volume: 7, Issue:5 Topics: Drug Delivery Systems; Drug Design; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2006
Treatment of the 5q- syndrome. Hematology. American Society of Hematology. Education Program, 2006 Topics: Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2006
Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. Leukemia research, 2007, Volume: 31, Issue:4 Topics: Chromosome Aberrations; Chromosomes, Human, Pair 5; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Thalidomide	2007
Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer control : journal of the Moffitt Cancer Center, 2006, Volume: 13 Suppl Topics: Anemia; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Delivery Systems; Erythropoiesis; Erythropoietin; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Recombinant Proteins; Thalidomide; Treatment Outcome	2006
Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes. Cancer control : journal of the Moffitt Cancer Center, 2006, Volume: 13 Suppl Topics: Algorithms; Anemia; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Delivery Systems; Humans; Lenalidomide; Medical Oncology; Myelodysplastic Syndromes; Practice Guidelines as Topic; Risk Factors; Thalidomide	2006
The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Current opinion in hematology, 2007, Volume: 14, Issue:2 Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2007
The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:4 Topics: Amyloidosis; Antineoplastic Agents; Hematologic Neoplasms; Humans; Lenalidomide; Leukemia; Myelodysplastic Syndromes; Thalidomide	2007
Risk-based management of myelodysplastic syndrome. Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:1 Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles	2007
Control of hematopoiesis and apoptosis in MDS: more than FLIPing the coin. Leukemia research, 2007, Volume: 31, Issue:6 Topics: Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Azacitidine; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Differentiation; Endothelial Cells; Enzyme Inhibitors; Gene Expression Regulation; Hematopoiesis; Hematopoietic Stem Cells; Humans; Lenalidomide; Monocytes; Myelodysplastic Syndromes; Signal Transduction; Stromal Cells; T-Lymphocytes; Thalidomide	2007
Myelodysplasia: the good, the fair and the ugly. Best practice & research. Clinical haematology, 2007, Volume: 20, Issue:1 Topics: Antilymphocyte Serum; Antineoplastic Agents; Azacitidine; Bone Marrow Transplantation; Clinical Trials as Topic; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2007
Lenalidomide: the emerging role of a novel targeted agent in malignancies. Drugs of today (Barcelona, Spain : 1998), 2007, Volume: 43, Issue:2 Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Thalidomide	2007
Lenalidomide in myelodysplastic syndrome and multiple myeloma. Drugs, 2007, Volume: 67, Issue:13 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide	2007
Immunomodulatory drugs in the treatment of myelodysplastic syndromes. Current opinion in oncology, 2007, Volume: 19, Issue:6 Topics: Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2007
Evaluating new treatment options for MDS. Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:11 Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; Epigenesis, Genetic; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide	2007
The role of lenalidomide in the management of myelodysplasia with del 5q. British journal of haematology, 2008, Volume: 140, Issue:3 Topics: Anemia, Refractory; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Outcome	2008
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Annals of hematology, 2008, Volume: 87, Issue:5 Topics: Antineoplastic Agents; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Humans; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Thalidomide	2008
[Development trend in new therapeutic approaches for anemia]. Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:3 Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles	2008
[Myelodysplastic syndrome]. Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:3 Topics: alpha Catenin; Antineoplastic Agents; Azacitidine; Cholecalciferol; Cyclosporine; Decitabine; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Thalidomide; Vitamin K 2; World Health Organization	2008

Trials

55 trial(s) available for lenalidomide and Myelodysplastic Syndromes

Article	Year
Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome. Bone marrow transplantation, 2021, Volume: 56, Issue:12 Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transplantation, Homologous	2021
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)". Leukemia, 2022, Volume: 36, Issue:5 Topics: Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	2022
Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 01-04, Volume: 29, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Benzoates; Hemorrhage; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Thrombocytopenia; Treatment Outcome	2023
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. Leukemia, 2020, Volume: 34, Issue:7 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Remission Induction; Survival Rate	2020
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 03-20, Volume: 39, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Epoetin Alfa; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Recombinant Proteins; Survival Rate	2021
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q). Annals of hematology, 2021, Volume: 100, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; DNA Methylation; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome	2021
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. Annals of hematology, 2017, Volume: 96, Issue:6 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antigens, CD34; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease-Free Survival; Female; Germany; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Leukemia, Myeloid; Leukocytes, Mononuclear; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Failure	2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Aug-20, Volume: 35, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Vorinostat	2017
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). Journal of hematology & oncology, 2017, 06-26, Volume: 10, Issue:1 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Cytogenetics; Disease Progression; Erythrocyte Transfusion; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide; Treatment Outcome	2017
Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. Leukemia & lymphoma, 2018, Volume: 59, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Diarrhea; Exanthema; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Risk Factors; Spasm	2018
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study. Clinical lymphoma, myeloma & leukemia, 2018, Volume: 18, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Double-Blind Method; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality of Life; Risk Factors; Surveys and Questionnaires	2018
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency. European journal of haematology, 2018, Volume: 101, Issue:1 Topics: Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Immunologic Factors; Italy; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Registries; Remission Induction; Retrospective Studies; Thalidomide	2018
Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. Annals of hematology, 2019, Volume: 98, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Venous Thrombosis	2019
Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide. Haematologica, 2019, Volume: 104, Issue:7 Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Bone Marrow; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; T-Lymphocyte Subsets; Tumor Microenvironment	2019
Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial. Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Erythrocyte Transfusion; Female; Hematinics; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Risk Assessment; Treatment Outcome	2019
Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:4 Topics: Administration, Oral; Aged; Anemia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Hematinics; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Prednisone; Treatment Outcome	2019
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. Leukemia research, 2019, Volume: 81 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Computational Biology; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Predictive Value of Tests; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult	2019
A variant erythroferrone disrupts iron homeostasis in Science translational medicine, 2019, 07-10, Volume: 11, Issue:500 Topics: Alternative Splicing; Amino Acid Sequence; Animals; Blood Transfusion; Cell Line; Cell Lineage; Cell Survival; Clone Cells; Erythroid Cells; Hepcidins; Homeostasis; Humans; Iron; Lenalidomide; Mice; Mutation; Myelodysplastic Syndromes; Peptide Hormones; Phosphoproteins; Protein Biosynthesis; RNA Splice Sites; RNA Splicing Factors; RNA, Messenger; Up-Regulation	2019
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Leukemia & lymphoma, 2013, Volume: 54, Issue:11 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Quality of Life; Thalidomide; Treatment Outcome	2013
Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients. European journal of haematology, 2013, Volume: 90, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Apoptosis; Bone Marrow Cells; Chromosome Aberrations; Chromosomes, Human, Pair 5; Disease-Free Survival; Erythroblasts; Female; Gene Expression Regulation; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Ribosomal Proteins; Survival Rate; Thalidomide	2013
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. Leukemia research, 2013, Volume: 37, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Chromosome Banding; Female; Follow-Up Studies; Germany; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Thalidomide; Time Factors; Treatment Outcome	2013
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leukemia research, 2013, Volume: 37, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide	2013
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. European journal of haematology, 2014, Volume: 93, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Disease Progression; Drug Administration Schedule; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk; Survival Analysis; Thalidomide; Treatment Outcome	2014
Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis. Leukemia research, 2014, Volume: 38, Issue:7 Topics: Aged; Aged, 80 and over; Biomarkers; Endothelial Cells; Humans; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Prospective Studies; Thalidomide; Vascular Endothelial Growth Factor A	2014
Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome. General physiology and biophysics, 2015, Volume: 34, Issue:4 Topics: Adult; Aged; Anemia, Macrocytic; Biomarkers; Blood Proteins; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Myelodysplastic Syndromes; Reproducibility of Results; Sensitivity and Specificity; Thalidomide; Treatment Outcome	2015
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leukemia & lymphoma, 2016, Volume: 57, Issue:3 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; BH3 Interacting Domain Death Agonist Protein; Biomarkers; Bone Marrow; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retreatment; Thalidomide; Treatment Outcome	2016
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia, 2016, Volume: 30, Issue:4 Topics: Aged; Anemia; Angiogenesis Inhibitors; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; Erythropoietin; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis; Prospective Studies; Risk Factors; Thalidomide	2016
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood, 2016, Feb-11, Volume: 127, Issue:6 Topics: Aged; Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Chromosome Deletion; Chromosomes, Human, Pair 5; Clonal Evolution; Clone Cells; DNA Mutational Analysis; Erythropoietin; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; Treatment Outcome	2016
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5). Leukemia, 2016, Volume: 30, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Prospective Studies; Thalidomide; Treatment Outcome	2016
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS). Leukemia, 2016, Volume: 30, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prevalence; Prospective Studies; Thalidomide; Tumor Suppressor Protein p53	2016
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 09-01, Volume: 34, Issue:25 Topics: Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Double-Blind Method; Drug Resistance; Erythrocyte Transfusion; Erythropoiesis; Female; Gene Expression; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Quality of Life; Thalidomide	2016
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol. Annals of hematology, 2016, Volume: 95, Issue:11 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites; Azacitidine; Bone Marrow; Disease-Free Survival; DNA Methylation; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Quality of Life; Risk; Thalidomide; Treatment Outcome	2016
A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. British journal of haematology, 2017, Volume: 176, Issue:2 Topics: Aged; Aged, 80 and over; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Salvage Therapy; Survival Rate; Thalidomide; Treatment Failure; Treatment Outcome	2017
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood, 2009, Apr-23, Volume: 113, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Survival Rate; Thalidomide; Treatment Outcome	2009
Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-20, Volume: 26, Issue:36 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia	2008
Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality. International journal of hematology, 2009, Volume: 90, Issue:3 Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Asian People; Chromosome Deletion; Chromosomes, Human, Pair 5; Chronic Disease; Female; Humans; Japan; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Thalidomide; Treatment Outcome	2009
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion. British journal of haematology, 2010, Volume: 148, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide	2010
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-01, Volume: 28, Issue:13 Topics: Aged; Azacitidine; Chromosome Aberrations; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Precancerous Conditions; Risk Assessment; Thalidomide; Time Factors; Treatment Outcome; United States	2010
Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. European journal of haematology, 2010, Volume: 85, Issue:3 Topics: Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Ribosomal Proteins; Risk Factors; Thalidomide; Transcription, Genetic	2010
Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jan-20, Volume: 29, Issue:3 Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Humans; Immunity, Cellular; Infant; Lenalidomide; Maximum Tolerated Dose; Myelodysplastic Syndromes; Neoplasms; Recurrence; Salvage Therapy; Thalidomide; Young Adult	2011
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica, 2011, Volume: 96, Issue:7 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 5; Female; Gene Expression Regulation, Leukemic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Oncogene Protein p21(ras); Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53; WT1 Proteins	2011
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood, 2011, Oct-06, Volume: 118, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Double-Blind Method; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Thalidomide	2011
Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. British journal of haematology, 2012, Volume: 156, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Administration Schedule; Drug Therapy, Combination; Female; Hematinics; Humans; Karyotype; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Thalidomide; Treatment Failure; Treatment Outcome	2012
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). Journal of hematology & oncology, 2012, Apr-30, Volume: 5 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; Female; Glutathione; Glutathione Transferase; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Prognosis; Thalidomide	2012
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Risk Factors; Thalidomide; Treatment Outcome	2012
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood, 2012, Dec-13, Volume: 120, Issue:25 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; DNA Mutational Analysis; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2012
Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood, 2012, Oct-25, Volume: 120, Issue:17 Topics: Aged; Antineoplastic Agents; Area Under Curve; Drug Administration Schedule; Drug Therapy, Combination; Erythropoietin; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Risk; Severity of Illness Index; Thalidomide; Thrombocytopenia; Treatment Outcome	2012
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. Annals of hematology, 2013, Volume: 92, Issue:1 Topics: Aged; Anemia, Macrocytic; Apoptosis; Bone Marrow Cells; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Forkhead Transcription Factors; Gene Dosage; Gene Expression Profiling; Gene Expression Regulation; Genetic Association Studies; Humans; Immunity, Innate; Lenalidomide; Male; MicroRNAs; Models, Genetic; Myelodysplastic Syndromes; Ribosomal Proteins; Signal Transduction; Thalidomide	2013
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. Journal of hematology & oncology, 2012, Nov-29, Volume: 5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Placebos; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombopoietin	2012
Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial. Leukemia research, 2013, Volume: 37, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Combined Modality Therapy; Cross-Over Studies; Double-Blind Method; Female; Health Status; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Placebos; Quality of Life; Risk; Severity of Illness Index; Thalidomide; Treatment Outcome	2013
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia, 2013, Volume: 27, Issue:6 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide	2013
Efficacy of lenalidomide in myelodysplastic syndromes. The New England journal of medicine, 2005, Feb-10, Volume: 352, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Angiogenesis Inhibitors; Bone Marrow; Female; Gene Deletion; Hematopoiesis; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia	2005
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. The New England journal of medicine, 2006, Oct-05, Volume: 355, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Erythrocyte Transfusion; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Thalidomide	2006
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood, 2008, Jan-01, Volume: 111, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide; Treatment Outcome	2008
Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment. Leukemia & lymphoma, 2008, Volume: 49, Issue:2 Topics: Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Kidney Diseases; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2008

Other Studies

215 other study(ies) available for lenalidomide and Myelodysplastic Syndromes

Article	Year
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proceedings of the National Academy of Sciences of the United States of America, 2007, Jul-03, Volume: 104, Issue:27 Topics: Antineoplastic Agents; Chromosome Deletion; Chromosome Mapping; Chromosomes, Human, Pair 5; Clone Cells; Erythroblasts; Gene Expression Regulation, Neoplastic; Growth Inhibitors; Humans; Lenalidomide; Myelodysplastic Syndromes; Osteonectin; Thalidomide; Tumor Cells, Cultured	2007
Toward a pathophysiology inspired treatment of VEXAS syndrome. Seminars in hematology, 2021, Volume: 58, Issue:4 Topics: Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Mutation; Myelodysplastic Syndromes; Transplantation, Homologous	2021
Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS). Clinical lymphoma, myeloma & leukemia, 2022, Volume: 22, Issue:7 Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Mutation; Myelodysplastic Syndromes; Phosphoproteins; Prognosis; Retrospective Studies; RNA Splicing Factors; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53	2022
[MDS with deletion 5q - a distinct subtype of myelodysplastic syndromes]. Therapeutische Umschau. Revue therapeutique, 2022, Volume: 79, Issue:2 Topics: Chromosome Deletion; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2022
Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche. British journal of haematology, 2022, Volume: 198, Issue:1 Topics: Anemia; Animals; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Macrophages; Mice; Myelodysplastic Syndromes; Thalidomide	2022
Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes. British journal of haematology, 2022, Volume: 198, Issue:3 Topics: Azacitidine; Clinical Trials, Phase II as Topic; Humans; Idarubicin; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Valproic Acid	2022
Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes. Clinical lymphoma, myeloma & leukemia, 2022, Volume: 22, Issue:9 Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Ferritins; Humans; Lenalidomide; Myelodysplastic Syndromes; Prospective Studies; Thalidomide; Treatment Outcome	2022
Quantitative evaluation of treatment response to lenalidomide by applying fluorescence in situ hybridization for peripheral blood granulocytes in a patient with 5q- syndrome. Journal of clinical and experimental hematopathology : JCEH, 2022, Sep-28, Volume: 62, Issue:3 Topics: Aged, 80 and over; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Cri-du-Chat Syndrome; Female; Granulocytes; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Trisomy	2022
Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting. American journal of hematology, 2022, Volume: 97, Issue:10 Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2022
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide. Blood cancer journal, 2022, 09-07, Volume: 12, Issue:9 Topics: Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2022
[Updated treatment strategies for myelodysplastic syndromes]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2022, Volume: 63, Issue:6 Topics: Antineoplastic Agents; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	2022
Images from the Haematologica Atlas of Hematologic Cytology: myelodysplastic syndrome with isolated del(5q). Haematologica, 2022, 10-01, Volume: 107, Issue:10 Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes	2022
Suspected Immune Thrombocytopenic Purpura Induced by Lenalidomide for the Treatment of Myelodysplastic Syndrome with Deletion of Chromosome 5q: A Case Report. The Tohoku journal of experimental medicine, 2023, Jan-21, Volume: 259, Issue:2 Topics: Aged; Chromosomes; Humans; Lenalidomide; Male; Multiple Myeloma; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia	2023
Treatment patterns in older patients with myelodysplastic syndromes: A population-based analysis reflecting the real world. Journal of geriatric oncology, 2023, Volume: 14, Issue:2 Topics: Aged; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Myelodysplastic Syndromes; Treatment Failure; Treatment Outcome	2023
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes. Clinical epigenetics, 2023, 02-20, Volume: 15, Issue:1 Topics: Azacitidine; DNA Methylation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; MicroRNAs; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-bcl-2	2023
What value do cell cycle inhibitors have in the treatment of myelodysplastic syndrome? Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:7 Topics: Cell Cycle; Humans; Lenalidomide; Myelodysplastic Syndromes	2023
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial. Haematologica, 2023, 11-01, Volume: 108, Issue:11 Topics: Adult; Azacitidine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Transfusion; Myelodysplastic Syndromes; Recurrence; T-Lymphocytes; Transplantation, Homologous	2023
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study. International journal of hematology, 2023, Volume: 118, Issue:4 Topics: Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; East Asian People; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Product Surveillance, Postmarketing; Thalidomide; Treatment Outcome	2023
Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation. Nature communications, 2023, 08-18, Volume: 14, Issue:1 Topics: Chromosome Aberrations; Female; Hematologic Neoplasms; Humans; Immunomodulating Agents; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Pregnancy; Proteolysis; Proteolysis Targeting Chimera	2023
[Current state of treatment for myelodysplastic syndromes]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2023, Volume: 64, Issue:9 Topics: Azacitidine; Genome-Wide Association Study; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis	2023
Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. American journal of hematology, 2020, Volume: 95, Issue:2 Topics: DEAD-box RNA Helicases; Germ-Line Mutation; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors	2020
The tale of lenalidomide clinical superiority over thalidomide and regulatory and cost-effectiveness issues. Ciencia & saude coletiva, 2019, Volume: 24, Issue:10 Topics: Angiogenesis Inhibitors; Brazil; Cost-Benefit Analysis; Drug and Narcotic Control; Drug Costs; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome	2019
Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels. Leukemia & lymphoma, 2020, Volume: 61, Issue:6 Topics: Erythrocyte Transfusion; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2020
Distinct mutational pattern of myelodysplastic syndromes with and without 5q- treated with lenalidomide. British journal of haematology, 2020, Volume: 189, Issue:4 Topics: Humans; Lenalidomide; Mutation; Myelodysplastic Syndromes	2020
Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome. Nature cell biology, 2020, Volume: 22, Issue:5 Topics: Cell Differentiation; Cell Line; Chromosomes, Human, Pair 5; Core Binding Factor Alpha 2 Subunit; Down-Regulation; GATA2 Transcription Factor; HEK293 Cells; Humans; Lenalidomide; Megakaryocytes; Mutation; Myelodysplastic Syndromes; Tumor Suppressor Protein p53	2020
Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro. Experimental hematology, 2020, Volume: 86 Topics: Animals; Apoptosis; Cell Line, Tumor; Cyclosporine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Ikaros Transcription Factor; Lenalidomide; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Muscle Proteins; Myelodysplastic Syndromes; Neoplasm Proteins; Up-Regulation; Xenograft Model Antitumor Assays	2020
Recalcitrant pemphigus successfully treated with lenalidomide. European journal of dermatology : EJD, 2020, Apr-01, Volume: 30, Issue:2 Topics: Aged, 80 and over; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Pemphigus; Remission Induction	2020
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients. Leukemia, 2021, Volume: 35, Issue:3 Topics: Biomarkers, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Mutation; Myelodysplastic Syndromes; Prognosis; Survival Rate	2021
[Management of lower-risk myelodysplastic syndromes]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2020, Volume: 61, Issue:9 Topics: Anemia, Macrocytic; Darbepoetin alfa; Humans; Japan; Lenalidomide; Myelodysplastic Syndromes; Risk Assessment	2020
Therapy for lower-risk MDS. Hematology. American Society of Hematology. Education Program, 2020, 12-04, Volume: 2020, Issue:1 Topics: Activin Receptors, Type II; Aged; Anemia; Blood Transfusion; Disease Management; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Fc Fragments; Lenalidomide; Male; Mutation; Myelodysplastic Syndromes; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin	2020
Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case. Revista medica de Chile, 2020, Volume: 148, Issue:9 Topics: Aged; Anemia, Macrocytic; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2020
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. American journal of hematology, 2021, 06-01, Volume: 96, Issue:6 Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Alleles; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Clonal Evolution; Disease Progression; Drug Resistance, Neoplasm; Female; Genes, p53; Humans; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Protein Phosphatase 2C; Retrospective Studies	2021
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia & lymphoma, 2021, Volume: 62, Issue:10 Topics: Aged; Anemia, Refractory; Chromosome Deletion; Chromosomes, Human, Pair 5; DNA; Humans; Lenalidomide; Medicare; Methyltransferases; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome; United States	2021
Efficacy of lenalidomide in a patient with systemic mastocytosis associated with Leukemia & lymphoma, 2021, Volume: 62, Issue:12 Topics: Humans; Lenalidomide; Mastocytosis, Systemic; Mutation; Myelodysplastic Syndromes; Phosphoproteins; RNA Splicing Factors	2021
Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin. Haematologica, 2022, 03-01, Volume: 107, Issue:3 Topics: Biomarkers; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes	2022
Age, Blasts, Performance Status and Lenalidomide Therapy Influence the Outcome of Myelodysplastic Syndrome With Isolated Del(5q): A Study of 58 South American Patients. Clinical lymphoma, myeloma & leukemia, 2022, Volume: 22, Issue:1 Topics: Age Factors; Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Analysis; Treatment Outcome	2022
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, May-10, Volume: 35, Issue:14 Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid	2017
Clonal evolution in myelodysplastic syndromes. Nature communications, 2017, 04-21, Volume: 8 Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Bone Marrow Cells; Clonal Evolution; Disease Management; Disease Progression; Drug Resistance, Neoplasm; Exome Sequencing; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Humans; Lenalidomide; Male; Membrane Proteins; Middle Aged; Monitoring, Physiologic; Mutation; Myelodysplastic Syndromes; Proto-Oncogene Proteins p21(ras); Thalidomide; Tumor Suppressor Protein p53	2017
pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4 Nature communications, 2017, 05-22, Volume: 8 Topics: Adaptor Proteins, Signal Transducing; Amino Acid Motifs; Animals; Antineoplastic Agents; Gene Deletion; HCT116 Cells; HEK293 Cells; Humans; Lenalidomide; Mass Spectrometry; Mice; Multiple Myeloma; Myelodysplastic Syndromes; Peptide Hydrolases; Proteomics; Substrate Specificity; Ubiquitin; Ubiquitin-Protein Ligases; Ubiquitination; Zinc Fingers	2017
Improving Outcomes in High-Risk Myelodysplasia: Festina Lente. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 08-20, Volume: 35, Issue:24 Topics: Azacitidine; Humans; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; United States; Vorinostat	2017
Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA. Journal of medical genetics, 2017, Volume: 54, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; DNA; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Microsatellite Repeats; Middle Aged; Multiplex Polymerase Chain Reaction; Myelodysplastic Syndromes; Reproducibility of Results; Thalidomide; Uniparental Disomy	2017
JSH Guideline for Tumors of Hematopoietic and Lymphoid Tissues: Leukemia: 6. Myelodysplastic syndromes (MDS). International journal of hematology, 2017, Volume: 106, Issue:2 Topics: Algorithms; Allografts; Azacitidine; Blood Transfusion; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Japan; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Prognosis; Risk; Thalidomide	2017
Population Pharmacokinetics of Lenalidomide in Healthy Volunteers and Patients With Hematologic Malignancies. Clinical pharmacology in drug development, 2018, Volume: 7, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Body Weight; Clinical Trials as Topic; Creatinine; Female; Healthy Volunteers; Humans; Lenalidomide; Male; Middle Aged; Models, Theoretical; Multiple Myeloma; Myelodysplastic Syndromes; Young Adult	2018
False-positive pregnancy tests in females of reproductive potential receiving lenalidomide in the United States. Leukemia & lymphoma, 2018, Volume: 59, Issue:4 Topics: Abnormalities, Drug-Induced; Adult; Ectromelia; False Positive Reactions; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Maternal-Fetal Exchange; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Pregnancy; Pregnancy Tests; United States	2018
Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence. Leukemia research, 2017, Volume: 60 Topics: Aged; Aged, 80 and over; Azacitidine; Blood Transfusion; Decitabine; Female; Hematinics; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Secondary Prevention; Thalidomide; Time Factors	2017
Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for. Clinical laboratory, 2017, Sep-01, Volume: 63, Issue:9 Topics: Chromosome Deletion; Dendritic Cells; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Plasma Cell; Thalidomide; Treatment Outcome	2017
"Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma. Blood, 2017, 09-28, Volume: 130, Issue:13 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cyclophosphamide; Cytoplasm; Dexamethasone; Diagnostic Errors; Erythroblasts; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Erythroblastic, Acute; Male; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide	2017
Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling. Leukemia, 2018, Volume: 32, Issue:2 Topics: Aged; Aged, 80 and over; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome	2018
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes. Haematologica, 2017, Volume: 102, Issue:12 Topics: Calgranulin B; Erythropoiesis; Erythropoietin; Hep G2 Cells; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha	2017
Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes. Leukemia research, 2017, Volume: 63 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Case-Control Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Thalidomide; Time Factors	2017
Emergence and evolution of Haematologica, 2018, Volume: 103, Issue:4 Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis; Tumor Suppressor Protein p53	2018
Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty? Leukemia & lymphoma, 2018, Volume: 59, Issue:9 Topics: Abnormalities, Multiple; Chromosome Deletion; Chromosomes, Human, Pair 2; Humans; Lenalidomide; Myelodysplastic Syndromes	2018
Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome. Leukemia research, 2018, Volume: 67 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Erythroblasts; Erythrocyte Indices; Erythropoiesis; Erythropoietin; Female; Hematopoietic Stem Cell Transplantation; Hemoglobins; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Survival Analysis; Young Adult	2018
Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients). Leukemia research, 2018, Volume: 69 Topics: Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Czech Republic; Erythropoietin; Female; Genes, p53; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prednisone; Recurrence; Remission Induction; Risk Factors	2018
Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes. American journal of hematology, 2018, Volume: 93, Issue:9 Topics: Aged; Aged, 80 and over; Blood Transfusion; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Off-Label Use; Survival Analysis	2018
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States. BMJ open, 2018, 07-23, Volume: 8, Issue:7 Topics: Aged; Aged, 80 and over; Anemia; Azacitidine; Databases, Factual; Decitabine; Electronic Health Records; Enzyme Inhibitors; Female; Hematinics; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Proportional Hazards Models; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; United States	2018
Blood, 2018, 10-04, Volume: 132, Issue:14 Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Casein Kinase I; Disease Models, Animal; Female; Hematopoiesis; Lenalidomide; Male; Mice; Mice, Inbred C57BL; Myelodysplastic Syndromes; Nerve Tissue Proteins; Point Mutation; Thalidomide	2018
Mutations and karyotype predict treatment response in myelodysplastic syndromes. American journal of hematology, 2018, Volume: 93, Issue:11 Topics: Aged; Antimetabolites, Antineoplastic; Dioxygenases; DNA-Binding Proteins; Female; Humans; Karyotype; Lenalidomide; Male; Mutation; Myelodysplastic Syndromes; Phosphoproteins; Prognosis; Proto-Oncogene Proteins; Repressor Proteins; RNA Splicing Factors; Splicing Factor U2AF; Treatment Outcome	2018
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q). Blood cancer journal, 2018, 09-21, Volume: 8, Issue:10 Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Prognosis; Treatment Outcome	2018
Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report. Medicine, 2019, Volume: 98, Issue:1 Topics: Aged; Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; B-Lymphocytes; Bone Marrow; Chromosome Deletion; Cyclophosphamide; Dexamethasone; Disease Progression; Enhancer of Zeste Homolog 2 Protein; Humans; Lenalidomide; Male; Mutation; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thrombocytopenia; Treatment Outcome	2019
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. Leukemia & lymphoma, 2019, Volume: 60, Issue:8 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Disease Management; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Treatment Outcome	2019
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. Leukemia, 2019, Volume: 33, Issue:9 Topics: Aged; Aged, 80 and over; Azacitidine; Cell Differentiation; Cell Proliferation; Disease-Free Survival; Female; Humans; Inositol; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes	2019
MDS with 5q deletion and rare BMJ case reports, 2019, Apr-20, Volume: 12, Issue:4 Topics: Anemia, Macrocytic; Biopsy; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Male; Mastocytosis; Middle Aged; Mutation; Myelodysplastic Syndromes	2019
Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome. British journal of haematology, 2019, Volume: 186, Issue:5 Topics: Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Prognosis; Progression-Free Survival; Survival Analysis	2019
One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic Expert review of hematology, 2019, Volume: 12, Issue:8 Topics: Antigens, CD; Azacitidine; CD8-Positive T-Lymphocytes; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Lymphocyte Activation Gene 3 Protein; Male; Middle Aged; Myelodysplastic Syndromes; Programmed Cell Death 1 Receptor; Recurrence; Transplantation, Homologous	2019
A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). Leukemia, 2013, Volume: 27, Issue:7 Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Chromosome Deletion; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Peptide Hydrolases; Polymorphism, Genetic; Risk; Thalidomide; Ubiquitin-Protein Ligases	2013
[Molecular target therapy for myelodysplastic syndrome]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 8 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytokines; Decitabine; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A	2012
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood, 2013, Jun-06, Volume: 121, Issue:23 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Thalidomide; Young Adult	2013
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. British journal of haematology, 2013, Volume: 162, Issue:1 Topics: Aged; Aged, 80 and over; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Thalidomide; Treatment Outcome	2013
Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica, 2013, Volume: 98, Issue:11 Topics: Aged; Cell Proliferation; Coculture Techniques; Cohort Studies; Female; Humans; Lenalidomide; Male; Mesenchymal Stem Cells; Middle Aged; Myelodysplastic Syndromes; Thalidomide	2013
Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. Cancer, 2013, Nov-01, Volume: 119, Issue:21 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Cohort Studies; Female; Humans; Lenalidomide; Male; Medicare; Myelodysplastic Syndromes; Practice Patterns, Physicians'; Thalidomide; Treatment Outcome; United States	2013
Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment? Leukemia & lymphoma, 2014, Volume: 55, Issue:6 Topics: Aged; Anemia, Macrocytic; Benzoates; Chromosome Deletion; Chromosomes, Human, Pair 5; Deferasirox; Erythroid Cells; Erythropoiesis; Female; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome; Triazoles	2014
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proceedings of the National Academy of Sciences of the United States of America, 2013, Oct-01, Volume: 110, Issue:40 Topics: Base Sequence; Dexamethasone; Drug Resistance; Erythroid Precursor Cells; Erythropoiesis; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lenalidomide; Molecular Sequence Data; Myelodysplastic Syndromes; Oligonucleotides; Real-Time Polymerase Chain Reaction; Sequence Analysis, DNA; Statistics, Nonparametric; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53	2013
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia, 2014, Volume: 28, Issue:5 Topics: Aged; Chromosome Deletion; Disease Progression; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Survival Analysis; Thalidomide	2014
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis. Leukemia research, 2014, Volume: 38, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Biomarkers, Tumor; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Survival Analysis; Thalidomide; Time Factors	2014
The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed. Leukemia research, 2014, Volume: 38, Issue:3 Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Thalidomide	2014
Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone. Leukemia & lymphoma, 2014, Volume: 55, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Benzoates; Cell Line, Tumor; Cell Proliferation; Clonal Evolution; Female; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Megakaryocyte Progenitor Cells; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Thalidomide; Thrombopoiesis	2014
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. British journal of haematology, 2014, Volume: 166, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Drug Evaluation; Erythrocyte Transfusion; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Thalidomide; Treatment Outcome	2014
[CME myelodysplasia - a frequent hematologic neoplasia in the elderly]. Praxis, 2014, May-21, Volume: 103, Issue:11 Topics: Aged, 80 and over; Anemia, Aplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Diagnosis, Differential; Disease Progression; Hematopoiesis; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Thalidomide	2014
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyrazines; Retrospective Studies; Thalidomide; Time Factors	2014
Successful treatment of an essential thrombocythemia patient complicated by Sweet's syndrome with combination of chemotherapy and lenalidomide. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:4 Topics: Aged; Blood Cell Count; Bone Marrow; Drug Therapy, Combination; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Nitrosourea Compounds; Skin; Sweet Syndrome; Thalidomide; Thrombocythemia, Essential; Treatment Outcome	2014
[Myelodysplastic syndromes (MDS)]. Nihon rinsho. Japanese journal of clinical medicine, 2014, Volume: 72, Issue:6 Topics: Azacitidine; Humans; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Thalidomide	2014
Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA). Annals of hematology, 2015, Volume: 94, Issue:3 Topics: Adult; Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Red-Cell Aplasia, Pure; Thalidomide	2015
Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q). Blood cancer journal, 2014, Aug-29, Volume: 4 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate; Thalidomide	2014
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. Leukemia & lymphoma, 2015, Volume: 56, Issue:6 Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2015
High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide. European journal of haematology, 2015, Volume: 95, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Anemia, Macrocytic; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 5; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Peptide Hydrolases; Polymorphism, Single Nucleotide; RNA Splicing; RNA, Messenger; Signal Transduction; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases	2015
Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide. European journal of haematology, 2015, Volume: 95, Issue:1 Topics: Aged; Anemia, Macrocytic; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 5; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Loci; Genome-Wide Association Study; Haploinsufficiency; Humans; Immunologic Factors; Lenalidomide; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Myelodysplastic Syndromes; Primary Cell Culture; RNA Splicing; Signal Transduction; Thalidomide	2015
Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring. Haematologica, 2015, Volume: 100, Issue:3 Topics: Antigens, CD; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Cohort Studies; Drug Monitoring; Female; Gene Expression; Humans; Immunologic Factors; Immunophenotyping; Lenalidomide; Lymphocytes; Male; Myelodysplastic Syndromes; Myeloid Cells; Thalidomide	2015
Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. PloS one, 2014, Volume: 9, Issue:12 Topics: Actins; Aged; Aged, 80 and over; Amides; Cell Line, Tumor; Drug Evaluation, Preclinical; Erythroid Precursor Cells; Female; Humans; Immunologic Factors; Lenalidomide; Male; Membrane Microdomains; Myelodysplastic Syndromes; Protein Multimerization; Pyridines; Receptors, Erythropoietin; rho-Associated Kinases; Signal Transduction; Thalidomide	2014
Myelodysplastic syndromes (MDS). Best practice & research. Clinical haematology, 2015, Volume: 28, Issue:1 Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Immunologic Factors; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2015
Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience. Leukemia & lymphoma, 2015, Volume: 56, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Comorbidity; Disease Progression; Erythrocyte Transfusion; Female; Follow-Up Studies; Gene Expression; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53	2015
Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment. Cancer genetics, 2015, Volume: 208, Issue:4 Topics: Angiogenesis Inhibitors; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 5; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; MicroRNAs; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Sequence Deletion; Thalidomide	2015
Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last? Hematological oncology, 2015, Volume: 33, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Hematologic Diseases; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Pain; Remission Induction; Thalidomide; Time Factors; Treatment Outcome	2015
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature, 2015, Jul-09, Volume: 523, Issue:7559 Topics: Amino Acid Sequence; Animals; Casein Kinase I; Cell Line; Gene Expression Regulation; HEK293 Cells; Humans; Immunologic Factors; Jurkat Cells; K562 Cells; Lenalidomide; Mice; Molecular Sequence Data; Myelodysplastic Syndromes; Peptide Hydrolases; Proteolysis; Sequence Alignment; Sequence Deletion; Species Specificity; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination	2015
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q). BMC cancer, 2015, Jul-08, Volume: 15 Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Poland; Retrospective Studies; Thalidomide; Treatment Outcome	2015
Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS. Leukemia research, 2015, Volume: 39, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Female; Humans; Kaplan-Meier Estimate; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Thalidomide; Tumor Suppressor Protein p53	2015
Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. PharmacoEconomics, 2016, Volume: 34, Issue:1 Topics: Anemia, Macrocytic; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cost-Benefit Analysis; Health Care Costs; Humans; Lenalidomide; Models, Economic; Myelodysplastic Syndromes; Quality-Adjusted Life Years; Technology Assessment, Biomedical; Thalidomide	2016
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence. Cancer medicine, 2015, Volume: 4, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Follow-Up Studies; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Quality of Life; Thalidomide; Treatment Outcome	2015
Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Angiogenesis Inhibitors; Austria; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Comorbidity; Disease Progression; Erythrocyte Transfusion; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Standard of Care; Survival Analysis; Thalidomide; Treatment Outcome	2015
Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retreatment; Retrospective Studies; Thalidomide; Treatment Failure; Treatment Outcome	2015
Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management. Drugs & aging, 2015, Volume: 32, Issue:11 Topics: Aged; Aged, 80 and over; Disease Management; Drug Therapy; Erythrocyte Transfusion; Female; Geriatric Assessment; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Male; Myelodysplastic Syndromes; Precision Medicine; Thalidomide; Thrombopoiesis	2015
Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse? Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Algorithms; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Approval; Drug Industry; Humans; Karyotyping; Lenalidomide; Methylation; Mutation; Myelodysplastic Syndromes; Prognosis; Risk Assessment; Thalidomide; United States; United States Food and Drug Administration	2015
Myelodysplastic syndrome. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2016, Jul-12, Volume: 188, Issue:10 Topics: Aged; Anemia, Macrocytic; Bone Marrow; Erythropoietin; Fatigue; Humans; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide	2016
[Lenalidomide treatment in myelodysplastic syndrome with 5q deletion--Czech MDS group experience]. Vnitrni lekarstvi, 2015, Volume: 61, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide	2015
Autoimmune diseases and myelodysplastic syndromes. American journal of hematology, 2016, Volume: 91, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azacitidine; Comorbidity; Disease Progression; Disease Susceptibility; Female; Follow-Up Studies; Hashimoto Disease; Humans; Immunocompromised Host; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prevalence; Proportional Hazards Models; Retrospective Studies; Thalidomide; Thyroiditis, Autoimmune; Young Adult	2016
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. Cancer medicine, 2016, Volume: 5, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cell Transformation, Neoplastic; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Registries; Retrospective Studies; Risk Factors; Thalidomide	2016
A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome. Leukemia & lymphoma, 2016, Volume: 57, Issue:11 Topics: Aged; Aged, 80 and over; DNA Methylation; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retreatment; Thalidomide; Treatment Outcome	2016
A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes. Nature medicine, 2016, Volume: 22, Issue:7 Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Calcium; Calcium-Binding Proteins; Calpain; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Peptide Hydrolases; Receptors, G-Protein-Coupled; RNA Interference; Thalidomide; Ubiquitin-Protein Ligases	2016
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nature medicine, 2016, Volume: 22, Issue:7 Topics: Adaptor Proteins, Signal Transducing; Basigin; Cell Cycle Proteins; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Oncogene Proteins; Peptide Hydrolases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Teratogenesis; Thalidomide; Ubiquitin-Protein Ligases	2016
Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia, 2016, Volume: 30, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Cohort Studies; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Thalidomide; Young Adult	2016
Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. Leukemia research, 2017, Volume: 52 Topics: Chromosome Aberrations; Cohort Studies; Computational Biology; Computer Simulation; Drug Resistance, Neoplasm; Humans; Lenalidomide; Myelodysplastic Syndromes; Protein Interaction Maps; Retrospective Studies; Thalidomide; Treatment Outcome	2017
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. Haematologica, 2017, Volume: 102, Issue:3 Topics: Aged; Aged, 80 and over; Biomarkers; Chromosome Deletion; Chromosomes, Human, Pair 5; Computational Biology; Disease Progression; Female; Gene Expression; Gene Expression Profiling; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Mesenchymal Stem Cells; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis; Stem Cell Niche; Thalidomide; Treatment Outcome	2017
Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide. BMJ case reports, 2017, Jan-04, Volume: 2017 Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Resistance; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Remission Induction; Thalidomide	2017
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. Oncotarget, 2017, Jun-06, Volume: 8, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Thalidomide; Treatment Outcome; Young Adult	2017
Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome. Annals of hematology, 2017, Volume: 96, Issue:6 Topics: Aged; Blood Transfusion; Comorbidity; Fatal Outcome; Female; Granuloma; Histiocytes; Humans; Lenalidomide; Multiple Organ Failure; Myelodysplastic Syndromes; Neutrophils; Paraneoplastic Syndromes; Prednisone; Thalidomide	2017
Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide. Leukemia & lymphoma, 2017, Volume: 58, Issue:10 Topics: Aged; Biomarkers, Tumor; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Prognosis	2017
Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis. Haematologica, 2008, Volume: 93, Issue:7 Topics: Adult; Blood Platelets; Chemistry, Pharmaceutical; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Male; Myelodysplastic Syndromes; Stem Cells; Syndrome; Thalidomide	2008
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. Journal of the National Comprehensive Cancer Network : JNCCN, 2008, Volume: 6, Issue:9 Topics: Anemia; Antineoplastic Agents; Azacitidine; Cost of Illness; Costs and Cost Analysis; Darbepoetin alfa; Decision Support Techniques; Deferoxamine; Drug Costs; Drug Therapy; Epoetin Alfa; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Recombinant Proteins; Siderophores; Thalidomide; United States	2008
[Myelodysplastic syndromes: therapeutic advances and promising future]. Medicina clinica, 2008, Oct-18, Volume: 131, Issue:13 Topics: Antineoplastic Agents; Azacitidine; Decitabine; Forecasting; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2008
Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. Cancer genetics and cytogenetics, 2008, Volume: 187, Issue:2 Topics: Algorithms; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Myelodysplastic Syndromes; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Prognosis; Spectral Karyotyping; Thalidomide	2008
Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality. Blood, 2009, Jan-29, Volume: 113, Issue:5 Topics: Antineoplastic Agents; Chromosomes, Human, Pair 13; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Retrospective Studies; Thalidomide; Trisomy	2009
The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells. Haematologica, 2009, Volume: 94, Issue:3 Topics: Aged; Antigens, CD34; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Female; Hematopoietic Stem Cells; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2009
Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques. Clinical drug investigation, 2009, Volume: 29, Issue:3 Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Databases, Factual; Erythropoiesis; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Product Surveillance, Postmarketing; Pulmonary Embolism; Risk Assessment; Thalidomide; United States; United States Food and Drug Administration; Venous Thromboembolism	2009
Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:12 Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Clinical Trials as Topic; Consensus; Decitabine; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide	2008
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proceedings of the National Academy of Sciences of the United States of America, 2009, Aug-04, Volume: 106, Issue:31 Topics: Antineoplastic Agents; Apoptosis; cdc25 Phosphatases; Chromosome Deletion; Chromosomes, Human, Pair 5; G2 Phase; Humans; Lenalidomide; Myelodysplastic Syndromes; Protein Phosphatase 2; Thalidomide; U937 Cells	2009
Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide. Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Erythropoietin; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Outcome	2009
Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough? Annals of hematology, 2010, Volume: 89, Issue:1 Topics: Aged; Female; Follow-Up Studies; Gene Deletion; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2010
A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q). Leukemia research, 2009, Volume: 33, Issue:11 Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2009
Successful treatment of MDS with lenalidomide, complicated by transient autoimmune hemolysis. Annals of hematology, 2010, Volume: 89, Issue:3 Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Female; Humans; Immunoglobulins; Lenalidomide; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2010
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer, 2009, Nov-15, Volume: 115, Issue:22 Topics: Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Monosomy; Myelodysplastic Syndromes; Prognosis; Risk; Survival Analysis; Thalidomide	2009
Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays. Best practice & research. Clinical haematology, 2009, Volume: 22, Issue:2 Topics: Antigens, CD34; Azacitidine; Cell Proliferation; Decitabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Myelodysplastic Syndromes; Protein Biosynthesis; Ribosomes; Thalidomide	2009
Clinical roundtable monograph. Combination therapies for MDS. Clinical advances in hematology & oncology : H&O, 2009, Volume: 7, Issue:7 Topics: Azacitidine; Carrier Proteins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colony-Stimulating Factors; Enzyme Inhibitors; Etanercept; Humans; Hydroxamic Acids; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Platelet Transfusion; Receptors, Fc; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Thalidomide; Thrombopoietin; Valproic Acid; Vorinostat	2009
Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica, 2010, Volume: 95, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 5; Colony-Forming Units Assay; Cytokines; Female; Flow Cytometry; Hematopoiesis; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide	2010
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica, 2009, Volume: 94, Issue:12 Topics: Aged; Antineoplastic Agents; Bone Marrow Cells; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Clone Cells; Disease Progression; Female; Gene Expression Profiling; Genetic Heterogeneity; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Mutation; Myelodysplastic Syndromes; Thalidomide; Tumor Suppressor Protein p53	2009
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Annals of hematology, 2010, Volume: 89, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Erythroid Cells; Female; Follow-Up Studies; Humans; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Thalidomide; Treatment Failure	2010
Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. Leukemia, 2010, Volume: 24, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; CD3 Complex; Cytokines; Female; Humans; Lenalidomide; Longitudinal Studies; Male; Middle Aged; Myelodysplastic Syndromes; Natural Killer T-Cells; Thalidomide	2010
Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q). Leukemia research, 2010, Volume: 34, Issue:7 Topics: Aged; Angiogenesis Inhibitors; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 9; Female; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Neoplasm, Residual; Remission Induction; Thalidomide	2010
Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia, 2010, Volume: 24, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Division; Cell Proliferation; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytokinesis; Fluorescent Antibody Technique; Gene Expression Profiling; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thalidomide; Tumor Cells, Cultured	2010
[Lenalidomide in the treatment of transfusion dependent myelodysplastic syndromes]. Ugeskrift for laeger, 2010, Feb-08, Volume: 172, Issue:6 Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A	2010
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leukemia research, 2010, Volume: 34, Issue:12 Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Thalidomide	2010
Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion. Haematologica, 2010, Volume: 95, Issue:3 Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2010
Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series. Annals of hematology, 2010, Volume: 89, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Clinical Trials as Topic; Cytogenetic Analysis; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Trisomy	2010
Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: a case report of sustained hematologic response following an abbreviated exposure. Journal of hematology & oncology, 2010, Apr-23, Volume: 3 Topics: Administration, Oral; Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 5; Erythroid Cells; Glutathione; Hemoglobins; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Remission Induction; Thalidomide; Treatment Outcome	2010
Myelodysplastic syndrome: An update on diagnosis and therapy. Current hematologic malignancy reports, 2009, Volume: 4, Issue:1 Topics: Antineoplastic Agents; Azacitidine; Cytogenetic Analysis; Decitabine; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Immunohistochemistry; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Severity of Illness Index; Thalidomide	2009
Management of myelodysplastic syndromes in the geriatric patient. Current hematologic malignancy reports, 2009, Volume: 4, Issue:1 Topics: Aged; Anemia; Antineoplastic Agents; Azacitidine; Decitabine; Erythrocyte Transfusion; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia	2009
Lenalidomide in myelodysplastic syndromes: where do we go from here? Current hematologic malignancy reports, 2008, Volume: 3, Issue:1 Topics: Antineoplastic Agents; Chromosome Deletion; Humans; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide	2008
Antiangiogenic therapy in myelodysplastic syndromes: is there a role? Current hematologic malignancy reports, 2008, Volume: 3, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Clinical Trials as Topic; Drug Approval; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Protein-Tyrosine Kinases; Thalidomide	2008
Lenalidomide induces remission and mixed quantitative chimerism fluctuations in refractory and relapsed myeloid malignancy with del (5). Leukemia research, 2010, Volume: 34, Issue:11 Topics: Adult; Antineoplastic Agents; Chimerism; Chromosome Deletion; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Remission Induction; Salvage Therapy; Sequence Deletion; Thalidomide	2010
Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide. Leukemia, 2010, Volume: 24, Issue:11 Topics: Aged; Anemia; Antineoplastic Agents; Cell Survival; Drug Therapy, Combination; Female; Hematinics; Hemoglobins; Humans; Lenalidomide; Myelodysplastic Syndromes; Sequence Deletion; Thalidomide	2010
Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q). Leukemia, 2010, Volume: 24, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Megakaryocytes; Middle Aged; Myelodysplastic Syndromes; Protein Array Analysis; Proteome; Sequence Deletion; Thalidomide; Treatment Failure; Treatment Outcome	2010
Persistent malignant stem cells in del(5q) myelodysplasia in remission. The New England journal of medicine, 2010, Sep-09, Volume: 363, Issue:11 Topics: ADP-ribosyl Cyclase 1; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Resistance; Female; Gene Expression; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neoplastic Stem Cells; Phenotype; Remission Induction; Thalidomide; Thy-1 Antigens	2010
Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation. Leukemia & lymphoma, 2010, Volume: 51, Issue:10 Topics: Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Mutation; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2010
Myelodysplastic syndromes--many new drugs, little therapeutic progress. Mayo Clinic proceedings, 2010, Volume: 85, Issue:11 Topics: Age Distribution; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Triazoles	2010
Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide. Haematologica, 2011, Volume: 96, Issue:2 Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cohort Studies; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Remission Induction; Risk Factors; Survival Rate; Thalidomide	2011
Three rearrangements of chromosome 5 in a patient with myelodysplastic syndrome: an atypical deletion 5q, a complex intrachromosomal rearrangement of chromosome 5, and a paracentric inversion of chromosome 5. Cancer genetics and cytogenetics, 2010, Volume: 203, Issue:2 Topics: Aged; Chromosome Banding; Chromosome Mapping; Chromosomes, Artificial, Bacterial; Chromosomes, Human, Pair 5; Cytogenetics; Gene Rearrangement; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide	2010
Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide. Leukemia research, 2011, Volume: 35, Issue:6 Topics: Acute Disease; Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Spectral Karyotyping; Thalidomide	2011
Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring. Haematologica, 2011, Volume: 96, Issue:2 Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Clone Cells; Humans; Lenalidomide; Myelodysplastic Syndromes; Remission Induction; Thalidomide	2011
Myelodysplastic syndrome presenting as generalized granulomatous dermatitis. Archives of dermatology, 2011, Volume: 147, Issue:3 Topics: Aged; Antineoplastic Agents; Biopsy; Blood Cell Count; Dermatitis; Disease Progression; Granuloma; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Pruritus; Thalidomide; Time Factors	2011
Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer, 2011, Apr-01, Volume: 117, Issue:7 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Remission Induction; Thalidomide; Treatment Outcome	2011
[The 5q- syndrome]. La Revue du praticien, 2010, Dec-20, Volume: 60, Issue:10 Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Thalidomide	2010
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis. Blood, 2011, Aug-25, Volume: 118, Issue:8 Topics: Anemia, Diamond-Blackfan; Coculture Techniques; Dexamethasone; Drug Therapy, Combination; Erythroid Precursor Cells; Erythropoiesis; Gene Expression Profiling; Humans; Lenalidomide; Myelodysplastic Syndromes; Ribosomal Proteins; Stromal Cells; Thalidomide	2011
Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. Annals of hematology, 2012, Volume: 91, Issue:2 Topics: Aged; Anemia; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2012
Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion. Leukemia research, 2011, Volume: 35, Issue:9 Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Hematologic Tests; Humans; Lenalidomide; Myelodysplastic Syndromes; Remission Induction; Thalidomide; Time Factors; Treatment Outcome	2011
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience. Leukemia research, 2011, Volume: 35, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Risk Factors; Thalidomide; Thrombocytopenia; Transfusion Reaction; Treatment Outcome	2011
Lenalidomide in del 5q MDS: responses and side effects revisited. Leukemia research, 2011, Volume: 35, Issue:11 Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide; Transfusion Reaction	2011
Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation. Leukemia research, 2011, Volume: 35, Issue:9 Topics: Amino Acid Substitution; Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Middle Aged; Mutation, Missense; Myelodysplastic Syndromes; Phenylalanine; Thalidomide; Treatment Outcome; Valine	2011
Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide. Leukemia, 2012, Volume: 26, Issue:2 Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Humans; Lenalidomide; Myelodysplastic Syndromes; Telomere; Thalidomide	2012
Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide. Leukemia, 2012, Volume: 26, Issue:4 Topics: Aged; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide	2012
The 5q- syndrome: biology and treatment. Current treatment options in oncology, 2011, Volume: 12, Issue:4 Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2011
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica, 2012, Volume: 97, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Cohort Studies; Disease Progression; Female; France; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Thalidomide; Treatment Outcome	2012
Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype. Leukemia, 2012, Volume: 26, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Thalidomide	2012
[Myelodysplastic syndrome in the elderly: comprehensive geriatric assessment and therapeutic recommendations]. Medicina clinica, 2012, Feb-18, Volume: 138, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Decision Support Techniques; Deferoxamine; Erythropoietin; Health Status Indicators; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Siderophores; Thalidomide	2012
[Myelodysplastic syndrome. What can be achieved with supportive therapy and new approaches]. MMW Fortschritte der Medizin, 2011, Nov-03, Volume: 153, Issue:44 Topics: Alemtuzumab; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Combined Modality Therapy; Erythrocyte Transfusion; Hematopoietic Stem Cell Transplantation; Hemochromatosis; Humans; Lenalidomide; Myelodysplastic Syndromes; Platelet Transfusion; Thalidomide	2011
Myeloma and second primary cancers. The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23 Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid; Melphalan; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Probability; Risk Assessment; Thalidomide	2011
Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study. Leukemia research, 2012, Volume: 36, Issue:5 Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythropoiesis; Humans; Lenalidomide; Megakaryocytes; Myelodysplastic Syndromes; Thalidomide	2012
Long-term transfusion independence in del(5q) MDS patients after short term therapy with lenalidomide: 2 new cases. Leukemia research, 2012, Volume: 36, Issue:5 Topics: Aged; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide	2012
Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation. Leukemia, 2012, Volume: 26, Issue:6 Topics: Antineoplastic Agents; Humans; Immune Tolerance; Lenalidomide; Myelodysplastic Syndromes; Prognosis; T-Lymphocytes; Thalidomide	2012
Pulmonary zygomycosis in a non-neutropenic patient with myelodysplastic syndrome on lenalidomide. Respiratory care, 2012, Volume: 57, Issue:7 Topics: Aged; Antineoplastic Agents; Fatal Outcome; Humans; Immunocompromised Host; Lenalidomide; Lung Diseases, Fungal; Male; Myelodysplastic Syndromes; Thalidomide; Zygomycosis	2012
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. Journal of hematology & oncology, 2012, Mar-05, Volume: 5 Topics: Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; DNA Methyltransferase 3A; Female; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Polymorphism, Single Nucleotide; Prognosis; Thalidomide	2012
Plasma exchange and rituximab treatment for lenalidomide-associated cold agglutinin disease. Transfusion, 2012, Volume: 52, Issue:11 Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Combined Modality Therapy; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Plasma Exchange; Rituximab; Thalidomide	2012
Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide? Haematologica, 2012, Volume: 97, Issue:10 Topics: Antigens, CD; Antineoplastic Agents; Bone Marrow Cells; Female; Humans; Immunophenotyping; Lenalidomide; Male; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide	2012
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene, 2013, Feb-28, Volume: 32, Issue:9 Topics: Animals; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Mice; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-mdm2; Thalidomide; Tumor Suppressor Protein p53; Ubiquitination	2013
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. Annals of hematology, 2012, Volume: 91, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles	2012
Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q). Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:5 Topics: Actin-Related Protein 2-3 Complex; Aged; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Gene Expression; Humans; Interleukin-1beta; Lenalidomide; Lipopolysaccharide Receptors; Male; Middle Aged; Monocytes; Myelodysplastic Syndromes; Prognosis; Proto-Oncogene Proteins c-jun; Signal Transduction; Stem Cell Niche; Thalidomide; Transcriptome; Tumor Necrosis Factor-alpha; Up-Regulation	2012
Improving the outlook for myelodysplastic syndrome. Journal of the National Cancer Institute, 2012, Aug-22, Volume: 104, Issue:16 Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; Disease Progression; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Methyltransferases; Molecular Targeted Therapy; Myelodysplastic Syndromes; Phosphoproteins; Point Mutation; Prognosis; Ribonucleoprotein, U2 Small Nuclear; Risk Assessment; RNA Splicing; RNA Splicing Factors; Spliceosomes; Thalidomide	2012
Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome. Haematologica, 2013, Volume: 98, Issue:3 Topics: Animals; Antigens, CD34; Chromosome Deletion; Chromosomes, Human, Pair 5; Gene Expression Regulation; Gene Knockdown Techniques; Hematopoietic Stem Cells; Humans; Lenalidomide; Mice; MicroRNAs; Myelodysplastic Syndromes; RNA, Messenger; Thalidomide; Treatment Outcome	2013
Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program. Leukemia & lymphoma, 2013, Volume: 54, Issue:4 Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Netherlands; Thalidomide; Treatment Outcome; White People	2013
Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q). Human pathology, 2013, Volume: 44, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosomes, Human, Pair 5; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Janus Kinase 2; Kaplan-Meier Estimate; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Sequence Deletion; Thalidomide	2013
Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Leukemia & lymphoma, 2013, Volume: 54, Issue:7 Topics: Azacitidine; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Failure; Treatment Outcome	2013
Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide. Leukemia & lymphoma, 2013, Volume: 54, Issue:9 Topics: Aged; Biopsy; Bone Marrow; Cytogenetic Analysis; Female; Humans; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide	2013
MDS: unraveling the mystery. Blood, 2012, Dec-13, Volume: 120, Issue:25 Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide	2012
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia, 2013, Volume: 27, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Retrospective Studies; Risk; Thalidomide	2013
The 5q- syndrome. Hematology (Amsterdam, Netherlands), 2004, Volume: 9, Issue:4 Topics: Age Factors; Antigens, CD; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Erythropoietin; Female; Gene Deletion; Genes, Tumor Suppressor; Humans; Immunosuppressive Agents; Lenalidomide; Male; Myelodysplastic Syndromes; Prognosis; Sex Factors; Thalidomide	2004
Myelodysplastic syndromes--coping with ineffective hematopoiesis. The New England journal of medicine, 2005, Feb-10, Volume: 352, Issue:6 Topics: Angiogenesis Inhibitors; Hematopoiesis; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2005
Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Annals of hematology, 2005, Volume: 84, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Karyotyping; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Survival Rate; Thalidomide	2005
Treatment of myelodysplastic syndromes. The New England journal of medicine, 2005, May-19, Volume: 352, Issue:20 Topics: Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2005
Treatment of myelodysplastic syndromes. The New England journal of medicine, 2005, May-19, Volume: 352, Issue:20 Topics: Angiogenesis Inhibitors; Antilymphocyte Serum; Blood Transfusion; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2005
New drug induces long-term MDS remission. Health news (Waltham, Mass.), 2005, Volume: 11, Issue:8 Topics: Chromosomes, Human, Pair 5; Gene Deletion; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2005
Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. Hematology. American Society of Hematology. Education Program, 2005 Topics: Angiogenesis Inhibitors; Antilymphocyte Serum; Antineoplastic Agents; Blood Transfusion; Cyclosporine; Granulocyte Colony-Stimulating Factor; Growth Substances; Hemoglobins; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide	2005
New agents in the treatment of MDS. Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:11 Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Enzyme Inhibitors; Humans; Indoles; Lenalidomide; Myelodysplastic Syndromes; Predictive Value of Tests; Thalidomide; Treatment Outcome	2005
Lenalidomide (Revlimid) for anemia of myelodysplastic syndrome. The Medical letter on drugs and therapeutics, 2006, Apr-10, Volume: 48, Issue:1232 Topics: Anemia; Chromosome Deletion; Chromosomes, Human, Pair 5; Contraindications; Female; Humans; Lenalidomide; Myelodysplastic Syndromes; Pregnancy; Pregnancy Complications; Thalidomide; Transfusion Reaction	2006
Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. Leukemia, 2006, Volume: 20, Issue:11 Topics: Acute Disease; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Point Mutation; Thalidomide	2006
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. Annals of hematology, 2007, Volume: 86, Issue:2 Topics: Adult; Aged; Chromosome Deletion; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2007
Lenalidomide: from bench to bedside (part 1). Cancer control : journal of the Moffitt Cancer Center, 2006, Volume: 13 Suppl Topics: Anemia; Antineoplastic Agents; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2006
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer control : journal of the Moffitt Cancer Center, 2006, Volume: 13 Suppl Topics: Antineoplastic Agents; Blood Transfusion; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cost-Benefit Analysis; Decision Support Techniques; Erythropoietin; Humans; Lenalidomide; Medical Oncology; Models, Econometric; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Recombinant Proteins; Risk Factors; Thalidomide; United States	2006
Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes. Cancer control : journal of the Moffitt Cancer Center, 2006, Volume: 13 Suppl Topics: Anemia; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Medical Oncology; Myelodysplastic Syndromes; Thalidomide	2006
Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome. Leukemia, 2007, Volume: 21, Issue:7 Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Thalidomide	2007
Managing myelodysplastic syndromes. Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:2 Suppl Nu Topics: Aged; Antineoplastic Agents; Bone Marrow Examination; Clinical Trials as Topic; Cytogenetic Analysis; Drug Monitoring; Erythrocyte Transfusion; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Oncology Nursing; Thalidomide	2007
Advances in MDS. Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:6 Topics: Antineoplastic Agents; Erythropoietin; Female; Granulocyte Precursor Cells; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide	2007
Advances in the treatment of MDS, multiple myeloma, and CLL. ONS connect, 2007, Volume: 22, Issue:8 Suppl Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Prognosis; Pyrazines; Risk Assessment; Thalidomide	2007
Lenalidomide, a thalidomide derivative, shows promise in various applications. ONS connect, 2007, Volume: 22, Issue:8 Topics: Antineoplastic Agents; Drug Monitoring; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Terminology as Topic; Thalidomide	2007
Myelodysplastic syndromes: introduction. Seminars in hematology, 2008, Volume: 45, Issue:1 Topics: Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Lenalidomide; Myelodysplastic Syndromes; Thalidomide	2008
Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide. Haematologica, 2008, Volume: 93, Issue:2 Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 5; Drug Resistance; Female; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Sequence Deletion; Thalidomide	2008
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS medicine, 2008, Volume: 5, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Cell Differentiation; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials, Phase II as Topic; Erythroid Precursor Cells; Erythropoiesis; Gene Expression Profiling; Genetic Markers; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Thalidomide	2008
Lenalidomide in myelodysplastic syndromes. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:4 Topics: Clinical Trials as Topic; Gene Deletion; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Remission Induction; Thalidomide	2008